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ABSTRACT

Advisor and Dissertation Chair: Glen Johnson, PhD, MA, MS
Background: Anaphylaxis is considered a severe, potentially fatal, systemic allergic reaction that
occurs suddenly after contact with an allergy causing substance. It is estimated that up to 5% of
the population has experienced anaphylaxis, with 1% of hospitalizations and 0.1% of emergency
department patients having fatal outcomes. The World Allergy Organization (WAO) reports that
the prevalence is at least 1.6%. Pediatric (≤16 years old) anaphylaxis was reported to have
increased from July 2008 through June 2016 from 11.8 to 38.7 presentations per 100,000 person
years. Whether adult or pediatric, it is believed the overall incidence of allergy and anaphylaxis is
increasing. The purpose of this dissertation is to investigate allergy and anaphylaxis through the
lens of the prehospital provider experience and the data developed from those patient encounters.
Methods: For Aim #1, we characterized the population of patients encountered by the EMS
agency that had a provider impression of “allergic reaction” and then utilized logistic regression
models to estimate associations with the administration of epinephrine in the prehospital setting.
For Aim #2, we used incident location data for all patient encounters of the EMS agency within
the borough of Staten Island to calculate kernel density estimates for the geographic region, and
then performed a cluster analysis of patients with a history of asthma or environmental allergy
using census tracts as the unit of aggregation. For Aim #3, we accessed patient records of
patients specifically transported to Northwell facilities to apply a screen based upon
NIAID/FAAN diagnostic criteria to identify potential cases of allergic reaction or anaphylaxis.
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These cases were then linked to hospital admission/discharge diagnoses for confirmation of the
results of the screen.
Results: For Aim #1, a total of 222,681 records were analyzed for this study, 131,054
patients were transported to hospitals (58.9%). There was a total of 786 patients identified with a
prehospital diagnosis of allergic reaction. Overall, provider impression of allergic reaction
accounted for ~0.6% of the population of patients transported to the hospital. 344 (44%) of the
cohort met a lenient interpretation of the NIAID/FAAN criteria for anaphylaxis, 324 (41%) met a
more restrictive interpretation of the NIAID/FAAN criteria, and 111 (14%) met the regional
anaphylaxis treatment and management protocol.

Out of 168 patients who were given

epinephrine by EMS providers (21% of all patients), 112 were age 18 or older (67%) and 98
(58%) were female. The odds of receiving epinephrine by EMS were significantly higher for
patients aged 11-17, as compared to those 18 years and older (OR 2.366; 95% CI 1.433, 3.907;
p=0.0008). For Aim #2, a total of 23,629 incidents resulted in 20,277 patient transports, 2,039
patients refusing care and/or transport, and 1,146 patients being transported by another agency
ambulance. Out of 23,462 incident locations with patient present, 15,461 (69%) patients had a
documented medication allergy history, 258 (1.17%) had only an asthma history, 239 (1.07%)
had only environmental allergy history, and 237 (1.06%) presented with all three-asthma history,
environmental and medication allergies. Cluster analysis of census tract aggregation of point
data indicated significant clusters of both elevated and lower relative risk for patients with
history of asthma, environmental allergies, or both. For Aim #3, a total of 222,681 records are
available to be analyzed. Of the 222,681 records, 131,054 patients were transported to hospitals
(58.9%). Of the total patients transported, we specifically identified only cases transported to
Northwell Health System facilities where it was possible to access electronic medical records for
v

admitting or discharge diagnosis and potential decision making (n=115,270, 51.7%). Only cases
where patients 18 years or older were used for this preliminary investigation (n=111,127,
49.9%). Patients transports for the period of January 1st, 2018 through August 2018 were
screened using a NIAID/FAAN anaphylaxis diagnostic criterion and additional four (4) cases on
anaphylaxis were identified (20% higher). A review of hospital charts of all transports to
Northwell facilities for the month of July 2019 identified 50% more cases than diagnosed
prehospitally.
Conclusion: This dissertation provides support for the position that pre-hospital research
may be conducted without the cross-validation of results with hospital-based assessment,
treatment, and management. The results are also generalizable to the overall emergency response
area and other participating agencies, since the policies, procedures, operations, personnel, and
protocols are consistent. It has brought a unique perspective to a geographic area that has a
population of over 8 million and may have up to 10% of people suffering from some type of
medication reaction, 8% having food allergies, and a rising prevalence of allergic diseases over
the last 50 years.
This dissertation was able to contribute by identifying hot spot locations for patients with
asthma histories for potential preventative intervention. It can be inferred that a substantially
sick population being transported by ambulance might be representative of an overall population
that might be adversely impacted by asthma and interventions undertaken to investigate and
improve the overall health of that population. Additionally, we were able to identify a unique
area of low relative risk that seems to contradict evidence of consistency of allergy sensitization
across census tracts.
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The dissertation was able to identify a structural issue with data as it is related to
medication allergy. This has potentially profound consequences to overall patient care in both
the hospital and pre-hospital settings. The failure of the provider in discriminating a medication
allergy from the overall category of adverse drug reactions (ADRs), and the lack of educating the
patient as to the differences, may lead to the patient being denied appropriate treatment for a
medical condition.
The apparent “simplistic” appearance of the NIAID/FAAN diagnostic criteria belies a
complex connection of patient history, signs and symptoms, and allergen triggers that may not
easily be visualized or conceptualized by providers. The limited time for hospital-based providers
to make the diagnosis before discharge or admission, as well as the much more limited patientprovider interaction in the prehospital setting, places pressure for the rapid identification of an
allergic reaction and anaphylaxis. A suggested allergy assessment process provides an algorithmic
approach to assessing each patient for an allergy, and then connecting the various facets of the
NIAID/FAAN criteria to suggest anaphylaxis may exist earlier in the patient-provider interaction.
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CHAPTER 1 – INTRODUCTION
Overview
An allergy is a hypersensitivity reaction to the presence of an agent (allergen), and
hypersensitivity is defined as the response of the body to any substance to which a patient has
increased sensitivity, being a general term for a variety of reactions.1 Anaphylaxis is considered a
severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an
allergy causing substance.2 It is estimated that up to 5% of the population has experienced
anaphylaxis, with 1% of hospitalizations and 0.1% of emergency department patients having fatal
outcomes.3-5 Diagnosis of anaphylaxis is difficult due to the complex nature of pathological
presentation.6 Multiple organ system involvement leads to a variety of signs and symptoms that
may be mistaken for other pathophysiological processes, resulting in a delay in diagnosis and
subsequent treatment. Delays in treatment have been associated with increased mortality.7, 8
Emergency medical services (EMS) are frequently called to assist patients with severe
allergic reactions or anaphylaxis, and the rapid identification of anaphylaxis and administration
of epinephrine is associated with positive health outcomes. In 2018, EMS units in the city of
New York responded to over 1.8 million calls, of which up to 11,000 patients may have been
experiencing severe allergic reactions or anaphylaxis. Early administration of epinephrine by
EMS personnel may reduce hospitalizations, lessen the need for additional doses of epinephrine
in the emergency department, a quicker return of normal vital signs, and decreased chance of
mortality.9-12
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Public Health Significance
Anaphylaxis
The true incidence of anaphylaxis is difficult to assess; however, there are life time risk
estimates ranging from 0.5-2.0% and the World Allergy Organization (WAO) reports that it is at
least 1.6%.13, 14 Pediatric anaphylaxis (<=16) has been reported to have increased over time from
11.8 to 38.7 presentations per 100,000 person years.11 Whether adult or pediatric, it is believed
the overall incidence of allergy and anaphylaxis is increasing.15-18 Prehospital administration of
epinephrine ranges from below 1% to as high as 45%, and common triggers include food, venom,
medications and other/unknown allergens. However, who is more likely to receive epinephrine,
and what type of allergen trigger is more prevalent, remains inconsistent among the studies. 4, 7, 1214, 16-24

In 2006, diagnostic criteria for anaphylaxis was released by the National Institute of
Allergy and Infectious Diseases (NIAID) and the Food Allergy and Anaphylaxis Network
(FAAN).17 Over the last 15 years, the use of this criteria to quickly identify and manage
anaphylaxis has proven a challenge in the Emergency Departments, with relatively low rates of
epinephrine administration. Epinephrine is the first-line treatment of choice for anaphylaxis, and
some severe allergic reactions, and can counteract many of the pathophysiological changes of
anaphylaxis by acting through α1 adrenergic receptors to induce vasoconstriction. This in turn
prevents and reduces tissue edema, hypotension, and distributive shock. Epinephrine also acts
through both β1 and β2 receptors to increase cardiac rate and contractility and dilate airways.19
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History of Prehospital Epinephrine and Anaphylaxis Management
In the prehospital setting, epinephrine administration for anaphylaxis was traditionally only
an option available to advanced life support personnel (ALS). However, over time, the safety
profile of the medication was deemed safe enough for basic life support providers to administer in
the field (2002). This initially started with only assisting the patient with their already prescribed
epinephrine autoinjector, and then progressed to equipping and authorizing autonomous use under
New York State Public Health Law Article 30 §3000-C. Due to the high cost of epinephrine
injectors for both patients and EMS agencies, a syringe epinephrine program was made a
demonstration project (“Check and Inject”) to determine the safety of allowing EMTs to draw up
epinephrine from a vial or ampule and administer through a syringe. In September of 2016, the
“Check & Inject” program was authorized for all regions of New York State, and in May 2017
was made a mandatory education component of original and refresher certification programs. An
assessment of the treatment of anaphylaxis over an entire system becomes possible to improve
patient identification and management.
There are some studies involving prehospital care (EMS) and anaphylaxis; however, in
contrast to hospital emergency department (ED) research, research involving anaphylaxis from the
prehospital perspective is extremely sparse. There is a common belief that, since most EMS
transports are directly connected to emergency department (ED) care by destination, the care
provided in the field is a direct extension of that provided in the ED.20 Therefore, there may be an
unjustified assumption that the patient characteristics and care is comparable to that which is being
observed in the ED.
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Prehospital Data and Research
EMS around the country are required to record patient encounter in reports that have
mandatory data fields. Although each state may have additional data elements, the basic set must
be reported to the National EMS Information System (NEMSIS), maintained under the oversight
of the National Highway Traffic Safety Administration (NHTSA) Office of EMS. The data
collected for this system provides researchers an opportunity to investigate a wide range of public
health issues including, but not limited to clinical, systems, and education in EMS.21-24 Research
has been strongly encouraged since 2001 when the National EMS Research Agenda was first
released by NHTSA and the Maternal Child Health Bureau.25

Asthma and Allergy Association
Neighborhood environmental factors have been linked to asthma including, but not limited
to, outdoor air pollutants, poor housing quality, and disproportionate pollution burdens found in
low-income, minority neighborhoods.26-30 There are also physical and social characteristics that
may impact individual health including poverty, residential segregation, inadequate transportation,
unsafe recreation spaces, and social networks.31 However, it has been suggested that the higher
prevalence of asthma in some inner-cities can be better explained by demographic factors, and not
simply by living in an urban environment.32
There is significant evidence to suggest that asthma and food allergies are associated, and
both increasing in prevalence.33, 34 Although it has been well researched, the exact relationship
between the two conditions is not fully understood.35 It has been suggested that a natural history
of atopy, a genetic tendency to develop allergic diseases, may provide a rationale of how food
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allergies and asthma relate and progress.36, 37 Asthma has also been identified as an associated risk
factor in fatal anaphylaxis.34
GISc Application Using Prehospital Data
Identifying where areas of allergy or asthma arises within a geographic area may provide
public health professionals an opportunity to intervene and improve overall health. Geographic
Information Systems Science (GISc) is able to track the acquisition, editing, analysis, storage and
visualization of geographic data.38 GISc provides a tool in which we can explore the manifestation
of asthma and allergy within a defined area, using the unique incident data contained within EMS
response records. GISc has been used to explore asthma in a number of environmental exposure
settings.39-43 GISc was also used to evaluate the neighborhood effects on childhood asthma, and
the impact of ethnicity and income on the prevalence of childhood asthma.26, 44 The use of GISc
to evaluate allergic diseases appears very limited, with only two (2) studies outside of the United
States being identified.45, 46
The use of GISc in EMS is not new; however, the application for disease conditions is very
limited. GISc has been applied to prehospital data to determine EMS unit locations for optimal
response, demand analysis for resources, access to services, and some surveillance of emerging
disease.47-51 Disease surveillance was limited to influenza outbreaks until the rise of SARS-CoV2 in 2020, when identifying general outbreak locations became a priority.52, 53 A 2016 study was
able to use location data from EMS cases of out-of-hospital cardiac arrest (OHCA) to identify
areas at high-risk for potential public health interventions.47, 54
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Modeling and Algorithms for Anaphylaxis
Emergency medical services (EMS) providers are taught a very structured methodology
in their approach to a patient.1 The patient assessment approach involves initial scene size-up, a
primary survey, history taking, a secondary assessment, and then re-assessment of the patient.
The primary survey involves a rapid evaluation of the patient for immediate life threats, and
actions by the provider to halt or reduce the untoward effects of discovered pathophysiological
manifestations. The patient’s allergy status is attempted during questioning of their past medical
history. This questioning is a mere rudimentary attempt to determine the existence of an allergy
history, what is (are) the inciting allergen(s), and the potential allergic response to the allergen.
Because of closely following this structured approach, prehospital emergency care providers do
not easily discern the signs and symptoms of complex disease processes like anaphylaxis as they
move through the various stages of the patient assessment.
An allergy assessment algorithm or model, to augment the simple questioning of whether
the patient has an existing allergy, could aid the provider in diagnosing severe allergic reactions
and anaphylaxis. An algorithm or model has the benefit of being like other algorithms familiar
to providers, while also eliciting a connection of the various body systems signs and symptoms
to allergen exposure, and time of onset consistent with the diagnostic criteria.55-60 The
NIAID/FAAN anaphylaxis diagnostic criteria, which was developed to aid physicians, could
potentially be modified to identify cases of anaphylaxis for EMS. We propose an initial
investigation into development and modeling of an algorithm, based upon EMS patient record
data, as a beginning step toward that goal.
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Specific Aims & Hypotheses
While fatal anaphylaxis events are a rare event in both the emergency department and
prehospital setting, the manifestation of anaphylaxis does not lend itself to predictable outcome.
Many cases of anaphylaxis resolve with limited intervention, while others quickly progress to
criticality from relatively benign initial symptoms.4, 61-63 Therefore, there is a direct benefit to a
patient to receive prompt treatment of anaphylaxis after identification to avoid the possibility of a
fatal outcome. There is also direct benefit to identifying potential geographic areas where
allergies may be present to address populations at risk. Finally, to aid in connecting the
information for this complex disease condition, an algorithm based upon prehospital data may
alert providers to the existence of anaphylaxis, resulting in improved management with
epinephrine.
Aim #1- Identify population characteristics including age, sex, and allergen type, and epinephrine
treatment for patients identified with allergic reactions in a metropolitan prehospital EMS
environment.
Hypothesis #1:

The characteristics of the population are comparable to those obtained
from hospital-based records research.

Hypothesis #2:

The incidence of anaphylaxis in the prehospital setting is comparable to
that of hospital emergency departments.

Aim #2- Use prehospital data to identify generalized, but unique, health-related issue locations
within a larger geographic area.
Hypothesis #2A:

Patients with history of asthma will be spatially clustered.
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Hypothesis #2B:

Patients with an environmental allergy history will be spatially clustered.

Aim #3-Use prehospital data to create an anaphylaxis algorithm to identify anaphylaxis patients
treated by providers in a metropolitan EMS agency.
Hypothesis #3A:

Data can be screened using the NIAID/FAAN criteria to identify
anaphylaxis patients.

Hypothesis #3B:

Identified anaphylaxis patient signs and symptoms, history, and
demographics can provide commonalities for a screening algorithm.

Overview of Methodology
Data was obtained through collaboration with the Northwell Center for Learning &
Innovation and the Center for Emergency Medical Services (CEMS). Data collected and stored
within the electronic medical records platform used by the Center for EMS was accessed for the
purposes of this dissertation and approval of institutional review boards of the City University of
New York and the Northwell Health System was obtained.
For Aim #1, we characterized the population of patients encountered by the EMS agency
that had a provider impression of “allergic reaction” and then utilized logistic regression models
to estimate associations with the administration of epinephrine in the prehospital setting.
For Aim #2, we used incident location data for all patient encounters of the EMS agency
within the borough of Staten Island to calculate kernel density estimates for the geographic
region, and then performed a cluster analysis of patients with a history of asthma or
environmental allergy using census tracts as the unit of aggregation.
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For Aim #3, we accessed patient records of patients specifically transported to Northwell
facilities to apply a screen based upon NIAID/FAAN criteria to identify potential cases of
allergic reaction or anaphylaxis. These cases were then linked to hospital admission/discharge
diagnoses for confirmation of the results of the screen.
Conclusion
In addition to filling some of the identified gaps in allergy and anaphylaxis knowledge
and research, another objective is to demonstrate the value of prehospital EMS data in research
not related to the normally applied systems operation. Although important, limited use of EMS
data to response time analysis, resource allocation, and access to services may underestimate and
ignore application elsewhere, including overall public health. The results of this dissertation will
demonstrate the utility of EMS generated data, use as a primary source, and in innovative
methods to evaluate disease processes not necessarily associated with the event.
It is in the setting of increasing allergy prevalence, that may lead to more cases of
anaphylaxis, in conjunction with suboptimal management of the disease process, that we put
forth this dissertation.
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CHAPTER 2 – CHARACTERIZING A
POPULATION OF PATIENTS WITH ALLERGIC
REACTIONS/ANAPHYLAXIS IN A
METROPOLITAN PREHOSPITAL EMS
ENVIRONMENT
Abstract
Background: Anaphylaxis is considered a severe, potentially fatal, systemic allergic reaction
that occurs suddenly after contact with an allergen and diagnosis of anaphylaxis is difficult due
to the complex nature of pathological presentation. Delays in treatment have been associated
with increased mortality. Research involving anaphylaxis from the prehospital perspective is
extremely sparse in contrast to hospital emergency department (ED) research. There may be an
unjustified assumption that the patient clinical presentation and care is comparable to that which
is being observed in the ED. Substantially different characteristics and outcomes in the
prehospital setting may be translated into, or have impact on, care provided within the ED.
Methods: A retrospective cohort study was conducted on prehospital patient records from January
1st, 2018 through December 31st, 2019. After characterizing the cohort with summary statistics,
logistic regression models were fit to estimate the association between signs and symptoms,
meeting of NIAID/FAAN diagnostic criteria, meeting regional anaphylaxis protocol criteria, and
the administration of epinephrine.
Results: 786 patient records from patients treated by both Basic Life Support (BLS) and Advanced
Life Support (ALS) units of the Northwell Health System, operating within the New York City
911 System. The pediatric population (<18 years) comprised 31% of the allergy and anaphylaxis
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cases, while the overall pediatric patient population transported by the agency was 6.1%. The
incidence of allergic reaction in the population transported by this EMS agency was 0.60%,
consistent with previous research reporting incidence of 0.5-1.0%. Forty-two percent of patients
with signs and symptoms consistent with the regional anaphylaxis protocol were given
epinephrine. Approximately 30% of patients meeting the NIAID/FAAN criteria had epinephrine
administered.
Conclusions: Overall, we were able to conclude that results from using only prehospital data was
consistent with hospital-based research findings, and the results can effectively “stand on their
own”. We were able to identify a structural deficiency in the prehospital electronic medical record
(EMR) that does not prompt or record an “allergen/trigger” for the allergic reaction or anaphylaxis
event. Male prevalence of allergic reactions at an earlier, and female prevalence at a later age, was
also observed with this population.

The results of this study failed to demonstrate any

differentiation between BLS and ALS units regarding patient age, gender, or potential allergic
trigger.
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Introduction
An allergy is a hypersensitivity reaction to the presence of an agent (allergen), and
hypersensitivity is defined as the response of the body to any substance for which a patient has
increased sensitivity, being a general term for a variety of reactions.1 However, anaphylaxis is
considered a severe, potentially fatal, systemic allergic reaction that occurs suddenly after
contact with an allergen.2 Diagnosis of anaphylaxis is difficult due to the complex nature of
pathological presentation.3 Multiple organ system involvement leads to a variety of signs and
symptoms that may be mistaken for other pathophysiological processes, resulting in a delay in
diagnosis and subsequent treatment. Delays in treatment have been associated with increased
mortality. 4, 5
There are some studies involving emergency medical services (EMS) prehospital care
and anaphylaxis; however, research involving anaphylaxis from the prehospital perspective is
extremely sparse in contrast to hospital emergency department (ED) research. There is a
common belief that, since most EMS transports are directly connected to emergency department
(ED) care by destination, and by medical oversight, the care provided in the field is a direct
extension of that provided in the ED.1 Therefore, there may be an unjustified assumption that the
patient clinical presentation and care is comparable to that which is being observed in the ED.
However, the “protocolized” nature of the care provided in the field, as well as the complex
presentation of anaphylaxis, may lead to substantially different characteristics and outcomes in
the prehospital setting. This in turn may be translated into, or have impact on, care provided
within the ED.
The true incidence of anaphylaxis is difficult to assess. Global incidence is estimated at
50-112 episodes per 100,000 person-years, and the lifetime prevalence estimates range from 0.316

5.1%. The World Allergy Organization (WAO) reports that the prevalence is at least 1.6%.6-8
Pediatric (≤16 years old) anaphylaxis was reported to have increased from July 2008 through
June 2016 from 11.8 to 38.7 presentations per 100,000 person years.7 Whether adult or pediatric,
it is believed the overall incidence of allergy and anaphylaxis is increasing.9-12. Prehospital
administration of epinephrine, the first-line treatment of anaphylaxis, ranges from below 1% to
as high as 45%.7, 12-14 Epinephrine can counteract many of the pathophysiological changes of
anaphylaxis by acting through α1 adrenergic receptors to induce vasoconstriction. This in turn
prevents and reduces tissue edema, hypotension, and distributive shock. Epinephrine also acts
through both β1 and β2 receptors to increase cardiac rate and contractility and dilate airways.15
Common triggers of anaphylaxis include food, venom, medications, and other/unknown
allergens. However, who is more likely to receive epinephrine, and what type of allergen trigger
is more prevalent, remains inconsistent among the studies.4, 7, 12-14, 16-24
It is the goal of this study to characterize the population of patients with allergic reactions
and/or anaphylaxis transported to the hospital, and to compare that population to existing
hospital-based evidence. We hope to estimate incidence of allergic reactions and anaphylaxis in
the population that is generalizable to the urban region, and to compare rates of epinephrine
administration between basic life support (BLS) and advanced life support (ALS) units.
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Methods
Study Design
A retrospective cohort study was conducted on prehospital patient records from January
1st, 2018 through December 31st, 2019. Both institutional review boards of the City University
of New York and the Northwell Health System approved this study with a waiver of informed
consent.
Setting
The study includes data obtained from the Emergency Medical Services (EMS) transports
of the Northwell Health System ambulance service operating inside the boundaries of the city of
New York, and within the municipal 911 system dispatched by the Fire Department of the City
of New York (FDNY). EMS care is determined by the protocols of the regional EMS council
(REMSCO) and Medical Advisory Committee (REMAC), under the oversight of the New York
State Department of Health, and upon the approval of the legislative authority of the New York
State EMS Council (SEMSCO) and Medical Advisory Committee (SEMAC), as delineated
under Article 30 of the New York State Public Health Law (PHL Article 30 §3002, §3002-a,
§3003, §3003-b).
The EMS agency operates twenty-seven (27) ambulances in the 911 system as a
voluntary participating, hospital-based agency under contract with the City of New York.
Ambulances are regionally deployed within the boroughs of Queens, Manhattan, and Staten
Island, but may be re-deployed anywhere within the confines of the City of New York, at the
direction of the Fire Department City of New York Communications Center. For the purposes of
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this study, only the patient records of the Northwell Health, Center for EMS NYC 911 Division
ambulance responses are being examined.
Data
Cases where the prehospital diagnosis (provider impression) of “Allergic Reaction” were
identified through a query of the prehospital database HealthEMS (Stryker Corp, Kalamazoo,
MI). The database was not queried to identify all potential cases of allergy/anaphylaxis with a
missed diagnosis, since this study was focused upon the perspective of the EMS personnel and
agency. Interfacility transports were excluded, as the management of the patient would have
been determined by the sending and/or receiving facility physicians’ assessment and
management, and not solely determined by the EMS provider.
Table 1.1-Overall Incident Volume

*Study period of January 1, 2018 through December 31, 2019.
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Variables
Variables collected include demographics, allergic trigger, signs and symptoms and other
variables as listed in Table 1.2 (Appendix A). In some cases, variables needed to be constructed
for analysis from those provided in the electronic medical records and are also indicated in that
table. A more thorough analysis required a manual review and abstraction of data from the
“Narrative Section” of the electronic medical record. The tool used for abstraction was
developed as part of the protocol for the study (Figure 1.1). Generalized signs and symptoms
were classified consistent with National Institute of Allergy and Infectious Disease/Food Allergy
and Anaphylaxis Network (NIAID/FAAN) criteria (i.e.- mucosocutaneous, respiratory,
cardiovascular, gastrointestinal)10 (Figure 1.2). Also, a review of the narrative section was the
only reliable method to ascertain potential allergic triggers.
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Figure 1.1-Abstraction Tool

*Categories coincide with NIAID/FAAN anaphylaxis criteria.

Figure 1.2-NIAID/FAAN Anaphylaxis Diagnostic Criteria

Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson Jr, N. F., Bock, S. A., Branum,
A., ... & Decker, W. W. (2006). Second symposium on the definition and management of
anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease
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Statistical Methods
Continuous data are summarized by the median and interquartile range (IQR). Categorical
data are presented as percent frequency of occurrence. Logistic regression models are fit to
estimate the dependence of epinephrine administration, coded as a binary outcome variable, on
signs and symptoms, meeting of NIAID/FAAN diagnostic criteria and meeting regional
anaphylaxis protocol criteria. Odds ratio (ORs) with 95% confidence intervals (CIs) are calculated
for each association.
Results
A total of 222,681 records were analyzed for this study, 108,561 from 2018, and 114,120
from 2019. Of the over 222,000 records, 131,054 patients were transported to hospitals (58.9%).
Of the 131,054 patient transports within the 911-system over the study period, 63,382 (48%)
occurred in 2018 and 67,672 (52%) occurred in 2019 (Table 1.1). There was a total of 786
patients identified with a prehospital diagnosis of allergic reaction, 391 in 2018 and 395 in 2019.
Overall, provider impression of allergic reaction accounted for approximately 0.6% of the
population of patients transported to the hospital, which was effectively the same for both 2018
(0.61%) and 2019 (0.58%). Three hundred forty-four (44%) of the cohort met a lenient
interpretation of the NIAID/FAAN criteria, 324 (41%) met a more restrictive interpretation of
the NIAID/FAAN criteria, and 111 (14%) met the regional anaphylaxis treatment and
management protocol (Table 1.3).

22

Table 1.3-Temporal/NIAID Variable Frequency (n = 786)
Temporal and Anaphylaxis Criteria
Variable
Day

Month

Year

Frequency
Sunday
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
January
February
March
April
May
June
July
August
September
October
November
December
2018
2019

NIAID/FAAN Criteria
NIAID/FAAN Criteria-R
Regional Prehospital Protocol Might Apply

105
97
129
131
107
121
96
50
53
64
65
49
80
60
83
70
75
66
71
391
395
344
265
111

% of
Total
13%
12%
16%
17%
14%
15%
12%
6%
7%
8%
8%
6%
10%
8%
11%
9%
10%
8%
9%
50%
50%
44%
34%
14%

Characteristics of Patients Transported for Allergic Reaction
The median age of the cohort was 28 years (IQR: 14-49). Two hundred forty-seven
(31%) patients were less than 18 years of age, and twenty-six (3%) of the patients were under 1
year of age. Four hundred and sixty-six (59%) patients were female, with a median age of 31
(IQR 18-51), as compared to male with a median age of 21 (IQR 7-44) (Table 1.4). One hundred
seventeen (15%) patients were identified as white, seventy-nine (10%) as black, sixty-seven
(9%) identified as Hispanic, and four hundred fifty-eight (58%) with race/ethnicity not specified
(Table 1.5). Food (48%) was the most identified trigger, followed by medications (18%), and
‘unknown’ (23%). Respiratory symptoms (39%) were the most common, followed by
cardiovascular (33%), mucosocutaneous (32%), and gastrointestinal (15%) (Table 1.6). One
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hundred thirty-two (17%) of the patients sought care at an urgent care facility prior to requesting
a 911 ambulance (Table 1.7).
Table 1.4-Age Characteristics by Categories Used in the Analysis.
Age Characteristics
Characteristics
N (%)
Median (IQR)
All Ages
786
28 (14-49)
By Gender
Female
466 (59)
31 (18-51)
Male
317 (40)
21 (7-44)
Missing
3 (1)
8 (2-70)
Age by Decade
Newborn to 9 Years
10 to 19 Years
20 to 29 Years
30 to 39 Years
40 to 49 Years
50 to 59 Years
60 to 69 Years
70 to 79 Years
80 Years and older
Missing

n (%)
156 (20)
117 (15)
143 (18)
91 (12)
83 (11)
77 (10)
57 (7)
35 (4)
25 (3)
2 (0.3)

Age by NIAID Criteria
Age <= 1 year
1 < age< 11 years
11 <= age < 18
Age >= 18 years
Missing

n (%)
30 (4)
139 (18)
78 (10)
537 (68)
2 (0.3)

Table 1.5-Race/Ethnicity Characteristics and Age Information for Largest Group.
Race/Ethnicity Characteristics
White
Black
Asian
Hispanic
Pacific Islander
Unknown
Race Not Specified
Native American

Cohort n (%)*
117 (15)
79 (10)
29 (4)
67 (9)
5 (1)
31 (4)
458 (58)
0 (0)

EMS Overall (%)*
28592 (13)
17483 (8)
3377 (2)
12772 (6)
753 (0)
6479 (3)
162210 (73)
188 (0)

Age Distribution
Median (IQR)
Race Not Specified
28 (13-49)
It should be noted that “Unknown” is an actual selected choice, where “Race Not Specified” indicates no field
was selected. EMS Overall category are a summary of all patient contacts during the study period. *-patients
may identify with more than one category.
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Table 1.6-Frequency of Signs and Symptoms
Signs & Symptoms
Mucosocutaneous
Airway
Partially or Fully Obstructed/ Drooling/Stridor*
Difficulty Swallowing/Voice Change*
Skin
Hives
Flushed
Swollen
Pruritis/Erythema/Rash*

n (%)
253 (32)
21 (3)
27 (3)
135 (17)
107 (14)
37 (5)
111 (14)

Respiratory
Effort
Dyspnea/SOB
Labored/Shallow Breathings*
Rate
Slow or Rapid Breathing
Quality
Diminished/Wheezing Lung Sounds*
Measurements
SPO2 <= 92
Respiratory rate > 24***

307 (39)

Cardiovascular
Lightheaded/Dizziness
Syncope
Chest Pain/Discomfort
Hypotension (Age Adjusted)
Tachycardia (Age Adjusted)

256 (33)
42 (5)
17 (2)
26 (3)
31 (4)
240 (31)

247 (31)
64 (8)
67 (9)
69 (9)
56 (7)
23 (3)

Gastrointestinal
117 (15)
Nausea
40 (5)
Vomiting
75 (10)
Abdominal Pain/Discomfort
27 (3)
Diarrhea
10 (1)
Observed within the identified cases where the provider impression was indicated as “Allergic
Reaction/Anaphylaxis”. *-Denotes the signs and/or symptoms were aggregated for analysis purposes. ***Denotes only applied to patients >18 years of age.

Table 1.7-Incident Location *
Location
Urgent Care
Other Location
Missing

Urgent Care Location
n (%)
Column1
132 (17)
653 (83)
1 (0)

Age Distribution
n (%)
Median (IQR)
All
132 (17)
37 (22-55)
Male
46 (35)
45 (16-66)
Female
85 (65)
32 (24-51)
*Where the patient sought medical care at a location prior to requesting an ambulance
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Gender, Age and Triggers
The distribution of age was analyzed continuously, categorically by decade, and
NIAID/FAAN anaphylaxis hypotension age criteria. Median age of the female population was
10 years older than the male (31 vs. 21), with an older and slightly narrower age range (IQR (1851) vs. IQR (7-44) (Table 1.4). A comparison of age by gender using decade categories
indicated a higher frequency of males with allergies when younger, and a higher frequency of
females with allergies when older starting in the second decade (𝜒2=19.7200, p=<0.0001) (Table
1.8). A comparison of age by gender using NIAID/FAAN age criteria indicated consistency
between genders, but females remained the predominant percentage after age 10 years of age
(𝜒2=36.8497, p<0.0001) (Table 1.9).
Table 1.8-Decade Age Category by Gender with percentages of gender in category.
Decade Age Category
0 to 9 years of age
10 to 19 years of age
20 to 29 years of age
30 to 39 years of age
40 to 49 years of age
50 to 59 years of age
60 to 69 years of age
70 to 79 years of age
80 years of age and older
Total

Decade Age Category by Gender
Female n
Male n
Column %
Column %
59
95
12.7
30.2
65
52
14.0
16.5
97
46
20.8
14.6
61
30
13.1
9.5
58
25
12.5
7.9
53
24
11.4
7.6
31
26
6.7
8.3
26
8
5.6
2.5
16
9
3.4
2.9
466
315

Total
154
117
143
91
83
77
57
34
25
781
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Table 1.9-NIAID/FAAN Age Category by Gender with percentages of gender in category.
Decade Age Category by Gender
NIAID Age Category
0 to 1 years of age
>1 to 10 years of age
>10 to <18 years of age
18 years of age and
older
Total

Female n
Column %
10
2.2
57
12.2
44
9.4
355
76.2
466

Male n
Column %
20
6.4
80
25.4
34
10.8
181
57.5
315

Total
30
137
78
536
781

The distribution of suspected triggers was similar between genders, except for
envenomation which was opposite the general distribution of 60% female (31%) (𝜒2=0.3023,
p=0.5824) (Table 1.10). The triggers analyzed by age indicated that the age of patients with food
triggers were significantly younger, and the age of patients with medication triggers significantly
older, than other triggers (Table 1.11). When age was categorized by decade and compared with
suspected triggers, food remained the most frequently encountered through the fifth decade of
life (𝜒2=21.3308, p<0.0001). Medication as a trigger remained relatively stable in the different
decade age categories, with a median of 19 cases for the decades of life after 29 years of age.
NIAID/FAAN criteria III uses hypotension criteria based upon age, and categorization by
hypotension age indicated food as the most frequent trigger for each category. “Unknown”
triggers were more frequent in the early decades of life and decreased significantly for those over
the age of 69.
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Table 1.10-Trigger by Gender
All Triggers
Food
Medicine
Envenomation
Environmental
Other
Unknown
Missing

All N(%)
786 (100)
381 (48)
143 (18)
13 (2)
17 (2)
43 (6)
183 (23)
6 (1)

Table 1.11-Trigger and Age Distribution
Trigger
Food
Medication
Envenomation
Environmental
Other
Unknown
Missing

Male n(%)
314 (40)
160 (51)
51 (16)
9 (3)
7 (2)
15 (5)
72 (23)

Female n(%)
463 (60)
220 (47)
91 (20)
4 (1)
10 (2)
28 (6)
110 (24)
9 (1)

n (%)
380 (49)
143 (18)
13 (2)
17 (2)
43 (5)
182 (23)
6 (1)

Median Age (IQR)
21 (9-36.5)
49 (30-64)
33 (5-44)
31 (17-48)
32 (22-54)
33 (14-55)
18 (11-23)

While controlling for gender, the relative odds of patient having a food trigger decreased
significantly as age increased past 29 years of age (Table 1.12a). Similarly, the relative odds of a
patient having a medication allergy increased significantly, compared to age group 0-9 years, as
age increased past 29 years of age (Table 1.12b). It should also be noted that the odds of having
a medication trigger appear elevated but stable after age 29 and increased substantially after age
60. While controlling for potential trigger source, the relative odds of being male appeared to
decrease after age 19. (Table 1.13).
Table 1.12a-Relative Odds of Having a Food Trigger among age categories, controlling for gender.
Age Category*
0 to 9 years of age
10 to 19 years of age
20 to 29 years of age
30 to 39 years of age
40 to 49 years of age
50 to 59 years of age
60 to 69 years of age
70 to 79 years of age
80 and over years of age
*-Controlling for Gender

OR
Reference
1.249
0.902
0.340
0.505
0.403
0.144
0.080
0.025

95% CI
Reference
0.751-2.077
0.560-1.453
0.197-0.587
0.291-0.875
0.228-0.711
0.069-0.300
0.026-0.239
0.003-0.190
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Table 1.12b-Relative Odds of Having a Medication Trigger among age categories, controlling
for gender
Age Category*
0 to 9 years of age
10 to 19 years of age
20 to 29 years of age
30 to 39 years of age
40 to 49 years of age
50 to 59 years of age
60 to 69 years of age
70 to 79 years of age
80 and over years of age
*-Controlling for Gender

OR
Reference
0.261
1.245
2.966
3.135
2.799
7.227
9.850
6.599

95% CI
Reference
0.073-0.934
0.579-2.678
1.410-6.240
1.472-6.676
1.284-6.102
3.369-15.502
4.079-23.789
2.486-17.515

Table 1.13-Relative Odds of Being Male as compared to female controlling for trigger, food as reference
ORs being Male Compared to Female
Age Category*

OR

95% CI

0 to 9 years of age

2.886

1.994-4.177

10 to 19 years of age

1.101

0.730-1.661

20 to 29 years of age

0.651

0.441-0.962

30 to 39 years of age

0.705

0.442-1.126

40 to 49 years of age

0.589

0.358-0.971

50 to 59 years of age

0.656

0.395-1.091

60 to 69 years of age

1.406

0.805-2.455

70 to 79 years of age

0.454

0.199-1.037

80 and over years of age

0.985

0.420-2.311

*-Controlling for potential trigger, food as reference.

Epinephrine Administration in the Prehospital Setting
Out of 168 patients who were given epinephrine by EMS providers (21% of all patients),
112 were age 18 or older (67%) and 98 (58%) were female. Epinephrine was administered prior
to EMS arrival in 202 patients (26% of all patients) and, of the patients not receiving epinephrine
prior to arrival, 494 (63%) did not receive epinephrine from EMS. The odds of receiving
epinephrine by EMS was significantly higher for patients aged 11-17, as compared to those 18
years and older (OR 2.366; 95% CI 1.433, 3.907; p=0.0008) (Table 1.14).
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Table 1.14-EMS Epinephrine Administration by Age, Gender, and Race/Ethnicity with unadjusted
odds ratio. PTA denotes epinephrine administered prior to arrival. Significant associations are highlighted.
EMS
No EMS
Epinephrine
Patient
Odds Ratio
Epinephrine Epinephrine*
PTA
p-value
Characteristic
(95% CI)
Given (n=168)
(n=618)
(n=202)
n (%)
n (%)
n (%)
All Ages
168
618
202
Age <= 1 year
3 (2)
27 (4)
9 (4)
0.421 (0.125-1.412)
0.1610
1 < age< 11 years
23 (14)
116 (19)
49 (24)
0.764 (0.466-1.252)
0.2850
11 <= age < 18
30 (18)
48 (8)
36 (18)
2.366 (1.433-3.907)
0.0008
Age >= 18 years
112 (67)
425 (69)
107 (53)
Reference
Reference
Missing
0 (0)
2 (0)
1 (0)
Age by Decade
Newborn to 9 Years
10 to 19 Years
20 to 29 Years
30 to 39 Years
40 to 49 Years
50 to 59 Years
60 to 69 Years
70 to 79 Years
80 Years and older
Missing

21 (13)
40 (24)
34 (20)
19 (11)
20 (12)
19 (11)
9 (5)
4 (2)
2 (1)
0 (0)

135 (22)
77 (13)
109 (18)
72 (12)
63 (10)
58 (9)
48 (8)
31 (5)
23 (3)
2 (0)

53 (26)
51 (25)
31 (15)
18 (9)
13 (6)
19 (9)
11 (5)
3 (1)
2 (1)
1 (0)

0.506 (0.278 - 0.922)
1.665 (0.968-2.865)
Reference
0.846 (0.448-1.597)
1.018 (0.540-1.918)
1.050 (0.551-2.003)
0.601 (0.268-1.350)
0.414 (0.136-1.255)
0.279 (0.063-1.244)

0.0262
0.0653
Reference
0.6060
0.9566
0.8818
0.2177
0.1341
0.0942

Gender
Female
Male
Missing

98 (58)
70 (42)
0 (0)

368 (60)
247 (40)
3 (0)

113 (56)
89 (44)
0 (0)

Reference
1.064 (0.753-1.505)

Reference
0.7249

Reference
0.390 (0.167-0.914)
1.385 (0.547-3.505)
0.914 (0.439-1.903)
0.865 (0.093-8.083)
1.648 (0.690-3.936)
0.988 (0.606-1.611)

Reference
0.0302
0.4923
0.8108
0.8991
0.2604
0.9602

Race/Ethnicity
White
26 (15)
91 (15)
49 (24)
Black
8 (5)
71 (11)
9 (4)
Asian
8 (5)
21 (3)
7 (3)
Hispanic
14 (8)
53 (9)
13 (6)
Pacific Islander
1 (1)
4 (1)
1 (0)
Unknown
10 (6)
21 (3)
4 (2)
Race Not Specified
101 (60)
357 (58)
119 (59)
Native American
0 (0)
0 (0)
0 (0)
*-Cases where epi not given prior to EMS arrival and treatment

Twenty-six (15%) of the patients identified by EMS as white received EMS epinephrine,
14 (8%) as Hispanic, and 8 (5%) as black. It should be noted that documentation of
race/ethnicity is not required on the mobile patient care records platform, and 458 (58%) patients
did not have a documented race/ethnicity. Black patients had a significantly lower odds of
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receiving epinephrine as compared to white patients (OR 0.394, 95% CI 0.168, 0.924) (Table
1.14).
One hundred patients (60%) received epinephrine from EMS when exposed to a potential
food trigger, twenty-eight (17%) for an unknown trigger, and nineteen (11%) for a medication
trigger. Food triggers were more frequently given epinephrine than other triggers (60%;
𝜒2=4.3839; p=0.0363). The odds of receiving epinephrine were significantly lower for both
medication and unknown triggers, as compared to food trigger (OR 0.431; 95% CI, 0.253, 0.735;
p=0.0020) and (OR 0.511; 95% CI, 0.321, 0.811; p=0.0044), respectively (Table 1.15).
Table 1.15-Epinepherine Administration by Suspected Trigger with odds ratio. Significant
associations are highlighted.
EMS
No EMS
Patient
Epinephrine PTA
Epinephrine
Epinephrine*
Odds Ratio (95% CI)
p-value
Characteristic
(n=202)
Given (n=168)
(n=494)
Trigger
n (%)
n (%)
n (%)
Food
100 (60)
208 (42)
113 (56)
Reference
Reference
Medicine
19 (11)
114 (23)
21 (10)
0.431 (0.253-0.735)
0.0020
Envenomation
2 (1)
7 (1)
5 (2)
0.507 (0.111-2.328)
0.3827
Environmental
3 (2)
13 (3)
2 (1)
0.598 (0.168-2.124)
0.4264
Other
14 (8)
24 (5)
14 (7)
1.347 (0.684-2.652)
0.389
Unknown
28 (17)
125 (25)
44 (22)
0.511 (0.321-0.811)
0.0044
*-Cases where epi not given prior to EMS arrival and treatment. PTA denotes epinephrine administered prior to arrival.

An analysis of epinephrine administration based upon day of week and month did not reveal
any significant changes in odds of getting the medication. The odds of receiving epinephrine in
2019 was significantly higher than 2018, OR 1.4671 (95% CI 1.040, 2.070; p=0.0292) (Table
1.16).
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Table 1.16-Epinepherine Administration by Temporal Characteristics with odds ratio. PTA denotes
epinephrine administered prior to arrival. Significant associations are highlighted.
EMS
No EMS
Patient
Epinephrine
Epinephrine
Epinephrine*
Odds Ratio (95% CI)
Characteristic
PTA (n=202)
Given (n=168)
(n=494)
Day
n (%)
n (%)
n (%)
Sunday
20 (12)
73 (15)
19 (9)
0.633 (0.331-1.209)
Monday
18 (11)
66 (13)
22 (11)
0.613 (0.315-1.193)
Tuesday
24 (14)
80 (16)
33 (16)
0.615 (0.332-1.137)
Wednesday
37 (22)
74 (15)
41 (20)
1.059 (0.598-1.875)
Thursday
29 (17)
62 (13)
32 (16)
Reference
Friday
22 (13)
75 (15)
36 (18)
0.598 (0.319-1.121)
Saturday
18 (11)
64 (13)
19 (9)
0.621 (0.319-1.209)
Month
January
February
March
April
May
June
July
August
September
October
November
December

18 (11)
10 (6)
20 (12)
14 (8)
10 (6)
17 (10)
12 (7)
14 (8)
10 (6)
16 (10)
14 (8)
13 (8)

25 (5)
32 (6)
35 (7)
35 (7)
37 (7)
48 (10)
41 (8)
60 (12)
50 (10)
47 (10)
42 (9)
42 (9)

p-value

0.1658
0.1495
0.1210
0.8445
Reference
0.1085
0.1607

18 (9)
14 (7)
20 (10)
20 (10)
8 (4)
25 (12)
9 (4)
16 (8)
13 (6)
20 (10)
18 (9)
21 (10)

2.049 (0.897-4.683)
0.847 (0.342-2.099)
1.656 (0.749-3.660)
Reference
0.934 (0.375-2.326)
0.983 (0.443-2.183)
0.911 (0.383-2.165)
0.739 (0.324-1.686)
0.607 (0.249-1.483)
0.988 (0.440-2.219)
0.981 (0.425-2.262)
0.817 (0.351-1.898)

0.0889
0.7201
0.2127
Reference
0.8835
0.9664
0.8324
0.4724
0.2736
0.9765
0.9637
0.6376

Year
2018
71 (42)
259 (52)
100 (50)
2019
97 (58)
235 (48)
102 (50)
*-Cases where epi not given prior to EMS arrival and treatment

Reference
1.467 (1.040-2.070)

Reference
0.0292

NIAID/FAAN Criteria and EMS administration of Epinephrine
Five hundred eighty-four (74%) patients did not receive epinephrine prior to arrival.
Eighty-one (10%) patients met the approved regional anaphylaxis protocol authorizing the use of
epinephrine. Thirty-four (42%) patients meeting the regional protocol received epinephrine and
fifty-six (11%) of patients not meeting regionally approved protocols received epinephrine (𝜒2
=50.9078; p<0.0001). Where epinephrine was not administered prior to arrival, the odds of a
patient receiving epinephrine while meeting the designated regional protocols as compared to not
meeting the protocols was OR 5.774 (95%CI 3.428, 9.727) (Table 1.17).
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Two different criteria models were used for analysis, one more restrictive than the other,
and designated NIAID/FAAN and NIAID/FAANR, respectively. Both criteria were less
restrictive than the regionally approved protocol. Of the 584 (74%) patients not receiving
epinephrine prior to arrival, 284 (42%) met NIAID/FAAN criteria and 229 (39%) met
NIAID/FAANR criteria. Seventy-one (29%) meeting NIAID/FAAN criteria received
epinephrine, and 19 (6%) not meeting the criteria received epinephrine (𝜒2=60.2313; p<0.0001).
Sixty-nine (30%) meeting NIAID/FAANR criteria received epinephrine, and 21 (6%) not
meeting the criteria received epinephrine (𝜒2=62.6173; p<0.0001). The odds of a patient
receiving epinephrine while meeting the NIAID/FAAN and NIAID/FAANR criteria as compared
to not meeting the criteria was OR 6.934 (95%CI 4.045, 11.886) and OR 6.859 (95%CI 4.063,
11.578), respectively (Table 1.17).
Table 1.17-Epinepherine Administration Meeting Anaphylaxis Criteria with unadjusted odds
ratio.

Characteristic

Overall

EMS
Epinephrine
Given n (%)

Odds Ratio (95% CI)

NIAID/FAAN
344
119 (35)
2.278 (1.684-3.080)
Criteria
NIAID/FAANR
324
114 (35)
2.235 (1.725-3.159)
Criteria
NYC
Adult/Pediatric
111
41 (37)
2.601 (1.731-3.908)
Protocol Might
Apply
*-Cases where epi not given prior to EMS arrival and treatment

p-value

<.0001
<.0001

<.0001

Epi not given
prior to EMS
Arrival
Odds Ratio
(95% CI)*
6.934 (4.04511.886)
6.859 (4.06311.578)

p-value

5.774 (3.4289.727)

<.0001
<.0001

<.0001

Basic Life Support (BLS) versus Advanced Life Support (ALS)
Six hundred fifteen (78.2%) of the patients were provided ALS level of care, and
epinephrine was administered 25.0% (n=154) of the time by ALS personnel (𝜒2 = 22.614;
p=<.0001). Distribution by gender was similar between ALS and BLS, 60.1% vs 57.3% female,
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respectively (𝜒2=0.4414; p= 0.5065). There was no significant difference by unit type in the
potential cases meeting the regional designated anaphylaxis protocol (14.5% vs. 12.9%;
𝜒2=0.2846; p=0.5937). However, a difference between ALS and BLS service was noted in the
percentage of cases potentially meeting the NIAID/FAAN criteria (44.6% vs. 29.2%;
𝜒2=12.9489; p=0.0004). The odds of receiving epinephrine from a BLS unit as compared to an
ALS unit, when regional anaphylaxis protocol may apply, was not significant (OR 0.755; 95%
CI, 0.279-2.039; p<0.5793) (Table 1.18).

Table 1.18-Epinepherine Administration by Service Level, Criteria, and Gender. Significant
associations are highlighted.
Criteria

Regional Protocol
NIAID/FAAN
NIAID/FAANR
Female
Male

BLS
(n=171)

ALS
(n=615)

n (%)
22 (13)
55 (32)
50 (29)
98 (57)
73 (43)

n (%)
89 (14)
289 (47)
274 (45)
368 (60)
244 (40)

BLS Epi
Given
(n=14)
n (%)
7 (50)
11 (79)
11 (79)
4 (29)
10 (71)

ALS Epi
Given
(n=154)
n (%)
34 (22)
108 (70)
103 (67)
94 (61)
60 (39)

Odds Ratio (95% CI)

p-value

ALS Reference
0.755 (0.279-2.039)
0.419 (0.208-0.846)
0.468 (0.230-0.955)
Reference
0.867 (0.313-1.251)

p=0.5793
p=0.0152
p=0.0368
Reference
p=0.7833

Overall Epinephrine Administration in the Prehospital Setting
Epinephrine was administered prior to EMS arrival to 202 (26%) of the patients and
provided by an urgent care provider in 59 (8%) of the patients (Table 1.19). When included in
the analysis of the overall administration of epinephrine, 111 (14%) patients met the regional
anaphylaxis protocol indicating the administration of epinephrine. Fifty-nine (53%) patients
meeting the regional protocol received epinephrine and 205 (30%) of patients not meeting
regionally approved protocols received epinephrine (𝜒2=22.1532; p<0.0001). The odds of a
patient receiving epinephrine while meeting the designated regional protocols as compared to not
meeting the protocols was OR 2.734 (95%CI 1.815, 4.119).
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Table 1.19-Epinepherine Administration Prior to Arrival of EMS. *
Administered By

Epinephrine PTA n (%)

All
Self
Other EMS
School
Bystander
Medical Provider
Other

202 (26)
44 (6)
6 (1)
35 (4)
55 (7)
61 (8)
1 (0)

Meeting Regional Protocol n
(%)
30 (4)
4 (1)
2 (0)
1 (0)
14 (2)
8 (1)
1(0)

Urgent Care Location
59 (8)
*- Other units arriving as part of the 911 response system are not included in this data.

8 (1)

Three hundred forty-four (43%) patients met NIAID/FAAN criteria and 324 (41%) met
NIAID/FAANR criteria. One hundred fifty-one (44%) meeting NIAID/FAAN criteria received
epinephrine, and 113 (25%) not meeting the criteria received epinephrine (𝜒2=29.1368;
p<0.0001). One hundred forty-five (45%) meeting NIAID/FAANR criteria received
epinephrine, and 119 (26%) not meeting the criteria received epinephrine (𝜒2=30.9061;
p<0.0001). The odds of a patient receiving epinephrine while meeting the NIAID/FAAN and
NIAID/FAANR criteria as compared to not meeting the criteria was OR 2.278 (95%CI 1.684,
3.080) and OR 2.335 (95%CI 1.725, 3.159), respectively (Table 1.20).
Table 1.20-Epinepherine Administration By Criteria and associated ORs.
Overall
Criteria
NIAID/FAAN
NIAID/FAANR
Regional Protocol Met

344
324
111

EMS
Epinephrine
Given n (%)
119 (35)
114 (35)
41 (37)

Epinephrine
PTA n (%)
100 (29)
95 (29)
30 (27)

All
Epinephrine
n (%)
151 (44)
145 (45)
59 (53)

OR (95% CI)
2.278 (1.684-3.080)
2.335 (1.725-3.159)
2.601 (1.731-3.908)

One hundred thirty-two (17%) of the patients were encountered in an urgent care location
(UCL), 59 (45%) patients received epinephrine prior to EMS arrival (𝜒2=29.8629; p<0.0001).
Sixteen (12%) of the patients met the designated regional protocols indicating treatment with
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epinephrine. When responding to an urgent care location, the odds of patients receiving
epinephrine when regional protocols indicate treatment, as compared when it not indicated, was
not significant when epinephrine administration prior to arrival is included in the analysis (OR
2.707; 95% CI, 0.884, 8.285) (Table 1.21).
Table 1.21-Criteria Met at Urgent Care Locations (UCL) and epinephrine administration. Significant
associations are highlighted.
Criteria (n=132)

UCL
n (%)

NIAID/FAAN
NIAID/FAANR
Regional Protocol Met

64 (48)
61 (46)
16 (12)

UCL Given
Epinephrine
n (%)
35 (55)
34 (56)
8 (50)

EMS Epi
given at UCL
n (%)
25 (40)
24 (39)
7 (44)

All Pts
Given Epi
n (%)
37 (58)
36 (59)
11 (69)

OR (95% CI)
2.278 (1.684-3.080)
2.214 (1.103-4.443)
2.707 (0.884-8.285)

Associations with Prehospital Administration of Epinephrine
Various signs and symptoms associated with epinephrine administration are contained in
Table 1.6 and 1.27 (Appendix E). Although comparatively low in frequency (3% of all cases),
patients presenting with partial or full airway obstruction, drooling, or stridor received the largest
percentage of epinephrine of the cases presenting with a sign or symptom, 67% (𝜒2=27.5443;
p<.0001). Where epinephrine was given overall, and when epinephrine was not given prior to
arrival (PTA), the cases also had a higher relative odd of receiving epinephrine than those not
presenting with partial or full airway obstruction, drooling or stridor (OR 8.250; 95% CI, 3.27020.813; p<0.0001) and (OR 12.665; 95% CI, 4.614-34.765; p<0.0001). Patients with labored or
shallow breathing, and those with diminished or wheezing lung sounds, were more likely to be
administered epinephrine by EMS (56%; OR 5.746; 95% CI, 3.387-9.750; p<0.0001) and (52%;
OR 4.835; 95% CI, 2.907-8.041); p<0.0001), respectively. Patients who received epinephrine
from EMS personnel, when not given prior to arrival, were more likely to have age-adjusted
hypotension and tachycardia, (OR 3.306; 95% CI, 1.473-7.420; p=0.0037) and (OR 3.562; 95%
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CI, 2.243-5.656; p<0.0001), respectively. An analysis of gastrointestinal signs and symptoms
did not reveal any statistically significant associations.
Age and Gender Effects on Associations
The effects of gender and/or age on select associations with prehospital epinephrine
administration are included in Tables 1.22, 1.23, 1.24, and 1.25. In almost all cases, the odds of
receiving prehospital epinephrine remains relatively unchanged. Although not statistically
significant, a gender effect is seen on the odds of receiving epinephrine in the older age groups,
with the males less likely to receive epinephrine after age 59, with decreasing OR estimates.
Table 1.22-Epinepherine Administration by Age Category, with and without controlling for
gender *
Characteristic

Odds Ratio (95% CI)
EMS Epi (Unadjusted)

p-value

Odds Ratio (95% CI)
Control for Gender

p-value

All Ages
Age <= 1 year
1 < age< 11 years
11 <= age < 18
Age >= 18 years

0.421 (0.125-1.412)
0.764 (0.466-1.252)
2.366 (1.433-3.907)
Reference

0.1610
0.2850
0.0008
Reference

0.404 (0.120-1.364)
0.741 (0.448-1.224)
2.339 (1.415-3.866)
Reference

0.1442
0.2416
0.0009
Reference

Age by Decade
Newborn to 9 Years
10 to 19 Years
20 to 29 Years
30 to 39 Years
40 to 49 Years
50 to 59 Years
60 to 69 Years
70 to 79 Years
80 Years and older

0.506 (0.278 - 0.922)
1.665 (0.968-2.865)
Reference
0.846 (0.448-1.597)
1.018 (0.540-1.918)
1.050 (0.551-2.003)
0.601 (0.268-1.350)
0.414 (0.136-1.255)
0.279 (0.063-1.244)

0.0262
0.0653
Reference
0.606
0.9566
0.8818
0.2177
0.1341
0.0942

0.484 (0.263-0.891)
1.636 (0.949-2.809)

0.0198
0.0764
0.6032
0.949
0.8781
0.2007
0.1403
0.0926
0.4187

0.845 (0.447-1.595)
1.021 (0.542-1.924)
1.052 (0.551-2.006)
0.589 (0.262-1.325)
0.433 (0.142-1.317)
0.277 (0.062-1.236)

Gender
Adj. for Age
Female
Reference
Reference Reference
Reference
Male
1.073 (0.759-1.517)
0.6908
1.043 (0.734-1.482)
0.8150
* Green highlighted categories show possible trends of interest for future investigation. Significant
associations are highlighted in gold.
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Table 1.23-Epinepherine Administration by Trigger Category Adjusted for Age and Gender.
Characteristic
Trigger
Food
Medicine
Envenomation
Environmental
Other
Unknown

Odds Ratio (95%
CI)
Unadjusted
Reference
0.431 (0.253-0.735)
0.507 (0.111-2.328)
0.598 (0.168-2.124)
1.347 (0.684-2.652)
0.511 (0.321-0.811)

p-value
Reference
0.0020
0.3827
0.4264
0.3890
0.0044

Odds Ratio (95%
CI)
Adj. Age
Reference
0.414 (0.235-0.731)
0.504 (0.110-2.313)
0.586 (0.164-2.090)
1.318 (0.664-2.616)
0.501 (0.312-0.804)

p-value
Reference
0.0023
0.3780
0.4101
0.4302
0.0042

Odds Ratio (95%
CI)
Adj. Gender
Reference
0.432 (0.253-0.737)
0.504 (0.109-2.320)
0.598 (0.168-2.124)
1.349 (0.685-2.658)
0.511 (0.321-0.812)

p-value

Odds Ratio (95% CI)

p-value

Reference
0.0021
0.3791
0.4266
0.3866
0.0045

Adj. Age & Gender
Reference
0.483 (0.272-0.859)
0.592 (0.126-2.787)
0.588 (0.162-2.131)
1.352 (0.675-2.709)
0.541 (0.335-0.873)

Reference
0.0133
0.507
0.4187
0.3942
0.0119

Table 1.24-Epinepherine Administration by Trigger category Adjusted for Signs & Symptoms *
Characteristic

Odds Ratio (95% CI)

Trigger

EMS Epi Given

Food
Medicine
Envenomation
Environmental
Other
Unknown

Reference
0.431 (0.253-0.735)
0.507 (0.111-2.328)
0.598 (0.168-2.124)
1.347 (0.684-2.652)
0.511 (0.321-0.811)

p-value

Reference
0.0020
0.3827
0.4264
0.3890
0.0044

Odds Ratio (95% CI)
Adj. Mucosocutaneous
S&Sx
Reference
0.454 (0.263-0.783)
0.426 (0.090-2.013)
0.571 (0.156-2.084)
1.279 (0.636-2.573)
0.510 (0.318-0.818)

p-value

Odds Ratio (95% CI)

p-value

Adj. Respiratory S&Sx
Reference
0.0045
0.2815
0.3960
0.4897
0.0053

Reference
0.451 (0.260-0.782)
0.652 (0.135-3.143)
0.538 (0.145-1.991)
1.185 (0.582-2.409)
0.562 (0.348-0.908)

Reference
0.0046
0.5938
0.3534
0.6401
0.0185

Odds Ratio (95% CI)
Adj. Cardiovascular
S&Sx
Reference
0.391 (0.227-0.672)
0.476 (0.102-2.209)
0.655 (0.183-2.348)
1.299 (0.654-2.579)
0.505 (0.317-0.806)

p-value

Reference
0.0007
0.3428
0.5160
0.4548
0.0042

Odds Ratio (95% CI)
Adj, Gastrointestinal
S&Sx
Reference
0.434 (0.254-0.742)
0.509 (0.111-2.337)
0.604 (0.170-2.149)
1.359 (0.688-2.685)
0.515 (0.322-0.823)

p-value

Reference
0.0023
0.3853
0.4358
0.3776
0.0055

* Highlighted categories show possible trends of interest for future investigation.

Table 1.25-Epinepherine Administration by Signs & Symptom Adjusted for Age and Gender *
Odds Ratio (95%
pOdds Ratio (95%
CI)
value
CI)
S & Sx
Unadjusted
Adj. Age
Mucosocutaneous
2.941 (2.066-4.188) <.0001 2.946 (2.068-4.195)
Respiratory
4.060 (2.825-5.835) <.0001 4.105 (2.853-5.907)
Cardiovascular
1.843 (1.297-2.620) 0.0006 2.097 (1.439-3.057)
Gastrointestinal
1.201 (0.755-1.912) 0.4394 1.179 (0.739-1.881)
* Highlighted categories show possible trends of interest for future investigation.
Characteristic

pvalue
<.0001
<.0001
0.0001
0.4905

Odds Ratio (95%
pCI)
value
Adj. Gender (ref=female)
2.959 (2.075-4.221) <.0001
4.060 (2.824-5.836) <.0001
1.845 (1.298-2.623) 0.0006
1.201 (0.755-1.912) 0.4397

Odds Ratio (95%
p-value
CI)
Adj. Age & Gender (ref=female)
2.973 (2.083-4.242)
<.0001
4.111 (2.856-5.916)
<.0001
2.098 (1.439-3.057)
0.0001
1.179 (0.739-1.881)
0.4899
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The results of a multivariable model for epinephrine administration are contained in
Table 1.26. With food triggers being the most treated allergic reaction and the reference
category, the results of the multivariable model appear to indicate that patients with medication
and unknown triggers were significantly less likely to receive epinephrine by EMS providers.
Signs and symptoms were combined into body system presentation for analysis and was not
compared to a reference category. Gender was coded for female reference category and age was
a continuous variable in this analysis. The results also indicate that gastrointestinal signs and
symptoms were not likely to influence the decision to administer epinephrine

Table 1.26-Multivariate Model for Epinephrine Administration with odds ratios. *
Characteristic
Odds Ratio (95% CI)
Trigger (Food Reference)
Medicine
0.492 (0.271-0.893)
Envenomation
0.582 (0.117-2.881)
Environmental
0.551 (0.142-2.145)
Other
1.213 (0.584-2.523)
Unknown
0.570 (0.343-0.945)
Signs & Symptoms
Mucosocutaneous
2.618 (1.792-3.824)
Respiratory
3.571 (2.441-5.226)
Cardiovascular
1.515 (1.007-2.278)
Gastrointestinal
1.069 (0.640-1.786)
Demographics
Gender
0.872 (0.592-1.284)
Age
0.995 (0.986-1.005)
* Significant associations are highlighted in gold.

p-value
0.0196
0.5067
0.3902
0.6043
0.0295
<.0001
<.0001
0.0461
0.7981
0.4877
0.3384

Sign and Symptom Presentation in the Prehospital Setting
The frequency of common signs and symptoms are presented in Table 1.27 (Appendix
E). Hives and flushed skin were the most encountered mucosocutaneous signs. Patient
described dyspnea or shortness of breath was the most encountered respiratory symptom. Ageadjusted tachycardia was the most common cardiovascular sign, while vomiting was the most
frequent gastrointestinal sign. This was consistent for all allergic reaction patients and those
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receiving epinephrine in the prehospital setting. The odds of receiving epinephrine by EMS
increased for most sign and symptom categories when it was not given prior to EMS arrival, with
the notable exceptions of difficulty swallowing/voice change (OR 1.462; 95% CI, 0.407-5.250;
p=0.5608) and pruritis/erythema/rash (OR 1.676; 95% CI, 0.951-2.956; p=0.0742) where the
odds became insignificant. It should also be noted that the odds of receiving epinephrine by
EMS became significant when it was not given prior to arrival for patients with age adjusted
hypotension OR 3.306; 95% CI, 1.473-7.420; p=0.0037).
Allergy History and Epinephrine Administration
Thirty-nine percent (n=310) of the patients with a provider impression of allergic reaction,
and 25% (n=28) of patients meeting the regional protocol for anaphylaxis treatment, did not have
documented history of allergies (𝜒2=21.039; p=0.0001). The odds of receiving epinephrine
while meeting the regional anaphylaxis treatment protocol was significantly less for patients with
no previous history of allergies, or those with a history of medication allergies, as compared to
those with environmental allergies (OR 0.291; 95% CI, 0.204-0.417; p=<.0001) and (OR 0.337;
95% CI, 0.188-0.606; p=0.0004).
Thirty-two percent (n=109) of patients meeting the NIAID/FAAN diagnostic criteria for
anaphylaxis treatment did not have a documented history of allergies (𝜒2=9.7369; p=0.0018).
The odds of receiving epinephrine while meeting the NIAID/FAAN diagnostic criteria, and like
the results for the regional protocol, was significantly less for patients with no previous history of
allergies, or those with a history of medication allergies, as compared to those with
environmental allergies (OR 0.580; 95% CI, 0.387-0.869; p=<.0083) and (OR 0.459; 95% CI,
0.232-0.908; p=0.0253) (Table 1.28).
40

Table 1.28-Odds of Receiving Epinephrine Depending on Allergy History and criteria.
Allergy History (Environmental Reference)

Odds Ratio (95% CI)

p-value

None

0.291 (0.204-0.417)

<.0001

Medication

0.337 (0.188-0.606)

0.0003

Both Medication and Environmental

0.877 (0.522-1.472)

0.6181

None

0.580 (0.387-0.869)

0.0083

Medication

0.459 (0.232-0.908)

0.0253

Both Medication and Environmental

0.633 (0.334-1.202)

0.1626

None

0.291 (1.414-3.310)

<.0001

Medication

0.337 (0.188-0.417)

0.0003

Both Medication and Environmental

0.877 (0.522-1.472)

0.6181

Regional Protocol

NIAID/FAAN Criteria

NIAID/FAANR Criteria

Discussion
There is a scarcity of studies involving prehospital care (EMS) and anaphylaxis from the
prehospital perspective.12, 14, 16, 17, 19 Most studies involve the identification of patients once
admitted to the ED and then work backwards toward the prehospital identification, management,
and treatment of anaphylaxis. The beginning point for this project was the identification of
patients with a prehospital diagnosis of allergic reaction. It should be noted that although the
National Emergency Medical Services Information System (NEMSIS) required data elements
contain a provider impression of “Allergic Reaction/Anaphylaxis”, the current state required
elements only contains “Allergic Reaction”.25 In either scenario, there is no easily discernible
distinction made between the two categories that would aid in identifying anaphylaxis patients
for evaluation of management and treatment in the prehospital setting without using a manual
screening tool.
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The use of a hospital admissions/discharge diagnosis as a “gold standard” from which to
compare prehospital presumptive diagnosis may be common; however, from the perspective of
the provider operating in a “protocolized” environment this comparison may not be appropriate.
The state and regional protocols are developed under the premise of identifying the most
immediate life threats, and then treating accordingly (Appendix B & Appendix C). Time,
resources, staffing, and evaluative testing are opportunities afforded to in-hospital patient care
but are not frequently available to prehospital providers. When one considers the complexities of
the anaphylaxis diagnosis in either the hospital ED or prehospital settings, it is necessary to
assess the unique environment to determine whether comparisons can be made or are
appropriate.
In addition to not having an entry in the prehospital care record for the unique
identification of anaphylaxis, there are also a few other issues that make the presumptive
diagnosis of anaphylaxis difficult, and the transference of that information to an in-hospital chart
complicated. The identification of a potential trigger of the allergic reaction is solely dependent
on the narrative entry by the prehospital provider. This has the potential of being easily rectified
by including several of the known trigger types (i.e.-food, medication, envenomation,
environment, or others) in an area under the provider impression for allergic
reaction/anaphylaxis. Also, the currently used electronic platform uses two (2) generalized
headings of “Medication Allergies” and “Environmental Allergies” and sub-category entries are
placed in a “text” note field of the record. The physical “paper” document has no such field and
relies on the provider to specify the allergen type and class in a narrative written form. Neither
of these methods of data gathering are efficient in the immediate identification of allergen to
potential trigger that is part of the NIAID/FAAN criteria for the diagnosis of anaphylaxis. It
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should be reiterated that the anaphylaxis diagnostic criteria II and III rely on identifying exposure
to a “likely allergen” or “known allergen” to the patient, respectively.
Frequency of Allergic Reaction and Anaphylaxis in the Prehospital Setting
The incidence of allergic reaction in this cohort is 0.56% of the total patient encounters
by the EMS service in the confines of the city, and 0.60% of all patients transported during the
study period. This is consistent with what has been previously reported by other studies of an
incidence between 0.5-1.0%. 12 This is slightly lower than what has been reported for emergency
department incidence of 1.3% of the patients seen.26, 27 If one assumes that every patient with a
prehospital provider impression of allergic reaction that received epinephrine is a case of
anaphylaxis, then the incidence of anaphylaxis is about 0.2%. Using the NIAID/FAAN criteria,
the incidence of anaphylaxis would be 0.25% and, if one assumed the NIAID/FAAN criteria in
conjunction with epinephrine administration, the incidence of anaphylaxis would be 0.11% for
all patients transported.
Higher Prevalence of Female Allergic Reaction/Anaphylaxis (Female More Severe Cases)
There is substantial evidence to indicate that gender plays a role in the development of
allergies, and prevalence of severe allergic reactions and anaphylaxis in females.28-33 In 2014, a
notable study demonstrated in mice that estrogen increased the severity of anaphylaxis through
increased nitric oxide production, thereby potentially explaining the increased prevalence in
females as they get older and enter puberty (>15 years of age).34 Although the evidence is less
compelling, testosterone is believed to be linked to reduced number of group 2 innate lymphoid
cells (ILC2s) that are regulators of immune response. As a result, the lack of progenitors leads to
reduced susceptibility to allergic airway disease, and potentially explains the reduced prevalence
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in males as they grow older.35 The results of our study demonstrate a “real world” manifestation
of the female prevalence in the prehospital environment. Assuming no other gender-related
factors influencing the decision, female utilization of emergency ambulance services more
frequently than male, by proxy, gives support to the proposition that females have more severe
allergic reactions and anaphylaxis than males.
Although there is a demonstrated female prevalence in the data involving allergic
reactions/anaphylaxis, the data also demonstrates a male prevalence at an earlier age and the
emergence of female dominance at ages above 20 years. This is consistent with evidence in
most of the prehospital and in-hospital studies involving allergic reactions and anaphylaxis.7, 16,
36, 37

However, there are a minority of studies that did not demonstrate that age-based gender

prevalence, and a study of pediatric patients in the same urban center demonstrated an almost
even split male vs. female (51% vs 49).14, 22
Age and Likelihood of Epinephrine by EMS
In this study, the use of epinephrine was less likely in the pediatric population age
newborn to 9 years compared to age 20-29 (OR 0.506; 95% CI, 0.278-0.922; p=0.0262), and age
group 11 to 17 was more likely to receive epinephrine as compared to those 18 years and older
(OR 2.372; 95% CI, 1.435-3.916, p=0.0007). When the analysis controls for gender, the odds of
receiving epinephrine decreases more profoundly for the newborn to 9 years of age group, as
compared to the age 20-29 years of age group and improves in significance (OR 0.263; 95% CI,
0.107-0.645; p=0.0035). The under-use of epinephrine in the infant to 10 years of age may be
potentially explained by the high probability that an epinephrine auto-injector (EAI) is carried
and administered by a caregiver, while it is more likely that an EAI is not carried by a person in
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the 10-19 year of age group, in conjunction with other factors such as risk-taking behavior, not
carrying or fear of using the device, not thinking it is necessary, or having an expired device.38-43
Hesitancy in treating younger pediatric patients, as well as potential errors in identification of
anaphylaxis by paramedics for this age group, may also influence the administration of
epinephrine. 44-46 The cumulative frequency plots of patients receiving epinephrine prior to
arrival by gender indicate a male bias in the earlier age groups and slightly later for female;
however, overall, the frequency of epinephrine given prior to EMS arrival is greater in the first
three decades of life (Figure 1.5-Appendix D).
An interesting effect was noticed when analysis controlled for gender when assessing the
effect of age on EMS epinephrine administration. Although not significant, the likelihood of
patients in the age category of 60-69, and 80 years and older, were less likely to receive
epinephrine as compared to patients aged 20 to 29, OR 0.344 (95% CI, 0.112-1.055; p=0.062)
and OR 0.168 (95% CI, 0.022-1.313; p=0.0891), respectively. To a lesser extent, the effect was
also noticed with the age group of 70-79 years of age (OR 0.404; 95% CI, 0.113-1.449;
p=0.1644). The population within these categories’ accounts for less than 15% of the total n for
this study, and those 50 and older accounts for 24.9%. A larger sample size might potentially
reflect something more significant, and these results are also consistent with existing evidence
indicating elderly are less likely to receive epinephrine for anaphylaxis.39, 47 This is of concern
due to a potential increase in the number of hospital admissions for anaphylaxis in the elderly
that has been noted in the same state.48
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Allergy History and Epinephrine Administration
For this cohort, using the NIAID/FAAN criteria as a basis of anaphylaxis diagnosis, the
incidence of new onset allergic reaction is 31% and new onset anaphylaxis at about 8%. This
finding is consistent with a 2017 review of 730 cases where they found 13.7% of the cases
referred after anaphylaxis as idiopathic, and far less than the 30-60% of cases reported in
ambulatory settings.49, 50 Medications and envenomation allergies are less common in children,
as compared to other triggers, and it has been suggested that up to 20% of the cases a trigger
cannot be identified.51,52,53
NIAID vs. NYC Protocol Comparison
Based upon the documented symptoms by the prehospital providers, we can estimate the
percentage of patients potentially meeting the criteria for anaphylaxis treatment according to the
regionally designated protocols and those meeting the NIAID/FAAN criteria. In this cohort,
where epinephrine was not given prior to arrival, 13.8% of the patients with a provider
impression of allergic reaction met the regional protocol for treatment with epinephrine
(anaphylaxis), and 15.4% of the patients with provider impression of an allergic reactions were
administered epinephrine. Epinephrine was administered to 42% of the patients with signs and
symptoms consistent with regional protocols and anaphylaxis, and 11.1% of patients with
allergic reactions were given epinephrine (non-anaphylaxis). (𝜒2=50.9078; p=<0.0001). An
argument can be made that the patients not receiving epinephrine and meeting the regional
protocol for anaphylaxis may have had reasonably low symptom severity. In these cases, the
provider may have determined epinephrine was not indicated.
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In comparison, 42% of the patients met the less restrictive NIAID/FAAN anaphylaxis
criteria and 39% met the more restrictive model for a potential diagnosis of anaphylaxis.
Twenty-nine percent and 30%, respectively, received epinephrine by EMS providers. Five-point
six percent and 5.9% of the patients with allergic reactions were given epinephrine (nonanaphylaxis). A similar argument can be made about symptom severity with the NIAID/FAAN
criteria potentially resulting in providers deciding against administration, as with the regional
designated protocol discussed above.
As was reported earlier, results indicate that gastrointestinal signs and symptoms are not
likely to influence the decision to administer epinephrine. This is consistent with the existing
regional protocol at the time, although it is a significant consideration in the NIAID/FAAN
criteria. Finally, the reduced odds of administering epinephrine to patients with cardiovascular
signs and symptoms, as compared to the other categories, is also consistent with regional
protocol that heavily emphasizes reduced blood pressure and shock symptoms for treatment
rather than being inclusive of other cardiovascular signs and symptoms such as chest pain and/or
discomfort.
Basic Life Support (BLS) versus Advanced Life Support
The results of this study failed to demonstrate any differentiation between BLS and ALS
units regarding patient age, gender, or potential allergic trigger. There is some indication that
BLS units may be dispatched to more patients that do not have a history of environmental or
medication allergies (46.8 vs. 37.4; 𝜒2=12.9273; p=0.0048). However, this could potentially be
explained by the emergency medical services dispatch platform used to determine priority and
type of response. For the most part, anaphylaxis and allergic reaction call types are a primary
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ALS unit response, and BLS units are dispatched when ALS is not immediately available or
delayed, or when the call intake information indicates a less severe allergic reaction.
When considering allergy history, the odds of receiving epinephrine from a BLS unit as
compared to an ALS unit, when regional anaphylaxis protocol may apply, was also not
significant (OR 0.742; 95% CI, 0.270-2.039; p=0.5626). However, when applied to the patients
that meet the NIAID/FAAN criteria for anaphylaxis, BLS units are significantly less likely to
administer epinephrine than ALS units (OR 0.306; 95% CI, 0.170-0.552; p=<.0001). A potential
explanation could be the differing levels of knowledge and experience between the two provider
levels that would guide the ALS provider more toward a diagnosis of anaphylaxis.
There are several studies that have evaluated prehospital providers’ diagnostic accuracy
in the areas of stroke, myocardial infarction, sepsis, and respiratory diseases; however, most of
these studies group all provider levels together, or specifically investigate paramedics alone.54-58
There is a systematic review and meta-analysis of pre-hospital diagnosis accuracy that reported a
pooled 74% sensitivity/94% specificity prehospital diagnostic accuracy. However, the authors
concluded that the lack of previous research and varying quality of the data warrants further
investigation in this area.59
The sensitivity and specificity of diagnostic accuracy may be of significant concern since
the NIAID/FAAN criteria include assessing the allergy history, and identification of a potential
trigger, in two of three criteria. The criteria have been both retrospectively and prospectively
evaluated, and the results have indicated the criteria is 96.7% sensitive/82.4% specific and 95.1%
sensitive/70.8% specific for anaphylaxis, respectively.60, 61 The inability of the prehospital
providers, due to either a knowledge gap or the data gathering process, to fully assess the
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NIAID/FAAN criteria can reasonably result in decreased effectiveness of the criteria and missed
opportunities to properly treat the patient with epinephrine. The protocol driven nature of
prehospital care makes application of the criteria problematic. However, protocol changes
implemented on January 1st, 2020 have integrated more aspects of the NIAID/FAAN criteria in
the statewide protocols that may improve the identification, management, and overall care of
patients with suspected anaphylaxis.
Limitations
This study carries with it the limitations of most retrospective cohort studies including
using data not specifically designed for the study and information bias. Although the data used
for this study was contained within the electronic medical records (EMRs) of the EMS agency, it
had to be gathered from both a query of the records and abstraction of the narratives that were
not able to be queried through normal electronic means. The various data sources were then
linked together through a common identification number in Microsoft Access, which was then
exported for use in SAS. The data queried from the EMR is also subject to incompleteness by
providers entering the data as well as an inaccurate provider impression based upon patient
history and presenting signs and symptoms. However, since most EMS personnel are trained to
document what they physically see or are told by the patient, it is believed that most data
elements are reliable for analysis.
The diagnosis of anaphylaxis is a complex process that may be difficult for EMS
providers to reach; however, relying on provider impression of allergic reaction as the base
building block from which to characterize this population places it completely within the
prehospital perspective. It was not the intent of this study to identify all potential cases
anaphylaxis or allergic reactions in the population, so a truly accurate incidence cannot be
49

revealed. However, the findings of this study are consistent with others and the incidence
appears to be similar.
Conclusion
This study attempts to further evaluate the assumption that the patient demographics, sign and
symptom characteristics, and management of allergic reaction/anaphylaxis patients being seen in
a hospital setting are equivalent to those identified in the prehospital setting. Utilizing
prehospital data allows for a system-wide overview that might indicate global differences that
may be ignored when using individual site ED data. The prevalence of food as a primary trigger
may differ from other studies; however, this may be due to the urban environment emphasizing
some triggers more than others (i.e., food in younger age group, medication in older age groups,
envenomations decreased overall). Typically, pediatric patients account for a smaller percentage
of overall cases transported; for this agency during the period of study, patients under the age of
18 constituted 5% of the total cases, and 0-9 years of age only 1.9% of the cases. However,
patients with allergic reaction/anaphylaxis under the age of 18 comprised about 31% of the
cases. This is an important finding as this indicates a counter-intuitive experience manifesting
in the pre-hospital environment.
Overall, this study provides support for the position that pre-hospital research may be
conducted without the cross-validation of results with hospital-based assessment, treatment, and
management. The results are also generalizable to the overall emergency response area and other
participating agencies, since the policies, procedures, operations, personnel, and protocols are
consistent. It has brought a unique perspective to a geographic area that has a population of
over 8 million and may have up to 10% of people suffering from some type of medication
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reaction, 8% having food allergies, and a rising prevalence of allergic diseases over the last 50
years.62
Our investigation was able to identify unique barriers to anaphylaxis diagnosis that
warrant additional action. The lack of an area to record a potential trigger in the patient care
documentation may result in a delay or missing of the inciting agent, and subsequent
development of anaphylaxis without early detection. Relying on a potential narrative entry for
this purpose is inefficient and does not allow for easy access of information or transfer of records
electronically. Anaphylaxis is a clinical diagnosis based on a complex interplay of multiple
system involvement, allergy history, and inciting allergen. The incongruous method in which
patient signs and symptoms, demographics, history of present illness, and past medical history
(including allergies) are recorded does not allow for diagnosis of anaphylaxis to be made easily
in the prehospital setting.
Our study affirms previous pre-hospital anaphylaxis research, but with a more diverse
and larger cohort. The frequency of allergic reactions and anaphylaxis is consistent with existing
hospital-based and prehospital research and gives support to the practice that population-based
research may be conducted with data obtained through prehospital sources. We were able to
demonstrate a “real-world” manifestation of a female prevalence in the presentation of allergic
reactions and anaphylaxis, which may also indicate a more severe case scenario. This
information may be used to augment EMS education platforms involving immunology and
allergic diseases.
This study was also able to identify age and epinephrine utilization issues involving EMS
personnel. There is a clear indication that the age group infant to 9 years of age may be under51

treated and an effort should be undertaken to educate providers that increases knowledge of
indications for epinephrine use, while reducing fear or anxiety in treating the younger age group.
Patients in the 11 to 17 age group have a significantly higher odds of getting epinephrine
prehospitally, and thus opens the opportunity for discussion on EAI usage and carriage at the
time of care and transport.
The significantly lower odds of receiving epinephrine when the patient has no
documented history of allergies is a finding of concern, especially considering the fact the EMS
personnel documented a provider impression of allergic reaction. The potential belief that “if the
patient does not have an allergy history, then it can’t be anaphylaxis” has significant care
ramifications for almost 32% of the patients in our study. Based on this finding’s implications, a
recommendation for an updated information bulletin was presented to the medical director of the
EMS agency.
The use of the NIAID/FAAN criteria alongside the regional approved protocol was able
to provide a comparison of care and management under different conditions. The NIAID/FAAN
criteria combine three different scenarios in which someone may develop anaphylaxis and does
so with a high degree of specificity and sensitivity. It is relatively independent of sign and
symptom severity and is identified through multi-system involvement, which is a hallmark of
anaphylaxis. It is understood that the regional protocols are a limited care scenario under the
premise of handling the most serious of cases prehospitally, and it relies heavily on sign and
symptom severity. The administration of epinephrine acts as a differentiating factor as to what
the prehospital provider currently understands as anaphylaxis versus allergic reaction. This
study established a benchmark activity to assess changes of the protocols that have gone into
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effect as of January 1st, 2020. This “natural experiment” will allow an analysis of changes to the
protocols to better correspond with NIAID/FAAN diagnostic criteria.
Finally, this study undertook an initial investigation into potential differences in BLS and
ALS unit management of anaphylaxis. If the dispatching protocol is indeed biased toward not
having a history of allergies as a precursor for low priority BLS assignment, then a suggestion to
improve provider education on allergic reactions and anaphylaxis in this population may be
warranted. This takes on added significance when trying to apply NIAID/FAAN diagnostic
criteria in this environment.
A strength of this study is that it contains a substantially large group of cases for analysis
that has a variety of both adult and pediatric patients, age groups, and race/ethnicity. It also
provides a benchmark of characteristics to compare the effects of the regional protocol changes
that were implemented after the end date of this study period.
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CHAPTER 3 – SPATIAL ANALYSIS OF
EMERGENCY MEDICAL SERVICES (EMS)
PATIENTS WITH HISTORY OF ASTHMA,
ENVIRONMENTAL ALLERGIES, OR BOTH IN A
METROPOLITAN AREA
Abstract
Background:

There is significant evidence to suggest that asthma and environmental allergies

may be associated, and that asthma is an associated risk factor in fatal anaphylaxis. We therefore
applied geospatial analyses to a cohort of prehospital patients with a history of asthma,
environmental allergies, or both, with the aim of identifying generalized, but unique, healthrelated issues of atopic disease within an urban environment.
Methods: Patient age, gender, incident location address, allergy history and both environmental
and medication allergy history were extracted from a prehospital database in the New York City
borough of Staten Island. After geocoding, Kernel Density Estimation (KDE) was applied for a
descriptive assessment of incident locations. We then applied the Bernoulli spatial scan statistic,
based on the ratio of cases to controls within census tracts, for inferential identification of both
elevated and depressed risk.
Results: Out of 23,462 incident locations with patient present, 15,461 (69%) patients had a
documented medication allergy history, 258 (1.17%) had only an asthma history, 239 (1.07%)
had only environmental allergy history, and 237 (1.06%) presented with all three-asthma history,
environmental and medication allergies. Significant asthma census tract clusters were identified
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in southwestern and southeastern Richmond county. A significant environmental allergy census
tract cluster was also identified in southwestern Richmond county.
Conclusions: We observed a general association between asthma and environmental allergy
clusters, with elevated and reduced relative risk occurring in the same geographic areas.
Locations of extreme asthma intensity were identified for potential intervention, including two
(2) NYCHA complexes. A unique area of low relative risk that seems to contradict evidence of
consistency of allergy sensitization across census tracts was identified for further investigation.
Medication allergies are not properly documented and are confused within the entire adverse
drug reaction category, requiring further provider education in the prehospital and hospital
environment.
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Introduction
Neighborhood environmental factors that have been linked to asthma include, but are not
limited to, outdoor air pollutants, poor housing quality, and disproportionate pollution burdens
found in low-income, minority neighborhoods.1-5 There are also physical and social
characteristics that may impact individual health including poverty, residential segregation,
inadequate transportation, unsafe recreation spaces, and social networks.6 However, it has been
suggested that the higher prevalence of asthma in some inner-cities can be better explained by
demographic factors, and not simply by living in an urban environment.7
There is significant evidence to suggest that asthma and environmental allergies,
specifically food, may be associated and both are simultaneously increasing in prevalence.8, 9
Although it has been well researched, the exact relationship between the two conditions is not
fully understood.10 It has been suggested that a natural history of atopy, a genetic tendency to
develop allergic diseases, may provide a rationale of how food allergies and asthma relate and
progress.11, 12 The Atopic March Hypothesis identifies “a typical sequence of progression of
clinical signs of atopic disease, with some signs becoming more prominent while others
subside.” Frequently food allergies in childhood precede development of asthma later in
childhood or adulthood. Asthma has also been identified as an associated risk factor in fatal
anaphylaxis.9
Geospatial Information Science (GISc) and spatial analytical methods have been applied
to several environmental subjects, including air pollution and asthma.13-15 GISc permits the
“…..integration of multiple layers of interdisciplinary spatial data, such as health,
environmental, genomic, social, or geographic data, for interactive spatial analysis and
modeling.” .16 Some example applications include assessment of asthma hospitalizations in
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relation to Toxic Release Inventories (TRIs), roadway pollution, and diesel particulate matter
(DPM). It is reasonable that similar geospatial analyses may advance the understanding of
atopic disease within an urban environment.
For the purposes of this project, we undertook a spatial analysis of a borough within the
city of New York (Staten Island) and performed a cluster analysis of patients being transported
by one of the Emergency Medical Services (EMS) agencies operating in the New York City 911
system. It is proposed that the use of prehospital data may be able to identify generalized, but
unique, health-related issue locations within a larger geographic area. For this study, we shall be
analyzing a population of patients with a history of asthma, environmental allergies, or both.
Methods
Study Design
This was a retrospective analysis of patient record data collected from January 1st, 2018
through December 31st, 2019. Both institutional review boards of the City University of New
York and the Northwell Health System approved this study with a waiver of informed consent.
Setting
The study includes data obtained from the Emergency Medical Services (EMS) transports
of the Northwell Health System ambulance service operating inside the boundaries of the city of
New York, and within the municipal 911 system dispatched by the Fire Department of the City
of New York (FDNY). EMS care is guided by the protocols of the regional EMS council
(REMSCO) and Medical Advisory Committee (REMAC), under the oversight of the New York
State Department of Health, and upon the approval of the legislative authority of the New York
State EMS Council (SEMSCO) and Medical Advisory Committee (SEMAC), as delineated
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under Article 30 of the New York State Public Health Law (PHL Article 30 §3002, §3002-a,
§3003, §3003-b).
The EMS agency operates ambulances in the 911 system as a voluntary participating,
hospital-based agency under contract with the City of New York. Ambulances are regionally
deployed within the boroughs of Queens, Manhattan, and Staten Island, but may be re-deployed
anywhere within the confines of the City of New York, at the direction of the Fire Department
City of New York Communications Center. For the purposes of this study, only the patient
records of the Northwell Health, Center for EMS NYC 911 Division ambulance responses in the
Borough of Staten Island are being examined.
Staten Island was selected for analysis for several reasons, operationally and
geographically. Northwell operates a larger percentage of the EMS units within this borough
than the others and functional access to both location and patient data was required for the study.
Staten Island is the least populated of the five (5) boroughs but has a higher median household
than all other boroughs except Manhattan ($82,783 vs. $86,553). However, based upon United
States Census Bureau Statistics, the household median income is more near the middle as
compared to surrounding New York and New Jersey counties. The borough also contains 170
parks, over 12,300 acres of protected land, and significant wetlands.

65

Data
Incident locations and documented history of asthma, environmental allergy, medication
allergy, age and gender were retrieved from the prehospital database, HealthEMS (Stryker Corp,
Kalamazoo, MI). Incidents were geocoded for analysis in ArcMap 10.7.1 (Esri, Inc., Redlands,
CA). Cases where the exact location was not provided by an incident address were excluded
from general analysis due to the higher probability of the patient not residing near the incident
location (i.e., major roadways, bridge crossings, highway intersections). Interfacility transports
were excluded, as the location of pickup or drop-off would coincide with a healthcare facility
and not necessarily reflective of where the patient resided, and invariably cause a cluster of cases
to coincide with that location.
Variables
Patient age, gender, incident location, allergy history and environmental and medication
allergy history were extracted from the database. After geocoding, incident location latitude and
longitude were used for cluster analysis. Age and gender are considered important variables due
to known differential allergy prevalence in the population.17-22
Statistical Methods
Continuous data are presented as median with interquartile range (IQR). Categorical data
are presented as percent frequency of occurrence. Kernel Density Estimates (KDE) for point
data involving patients with asthma history, environmental allergy history, and both asthma and
environmental allergy histories were thematically mapped to identify areas of further interest.
Cluster analysis was conducted with SaTScan Software for Spatial, Temporal, and Space-Time
Scan Statistics v9.7 (Boston, MA) to identify statistically significant clusters, which were
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thematically mapped according to cluster relative risk estimates. Bernoulli models were used for
cluster identification, based on the ratio of cases to controls within census tracts. Cases were
identified as patients with only asthma history, only environmental allergy history, or both
environmental allergy and asthma history. Controls were identified as all remaining patients.
Results
A total of 23,629 incidents resulted in 20,277 patient transports, 2,039 patients refusing
care and/or transport, and 1,146 patients being transported by another agency ambulance. A total
of 23,462 incident locations with patient present were used for analysis.
An analysis of patient history, age, and gender for the entire group is presented in Table
2.1. There were 15,461 (69%) patients with a documented medication allergy history, 3,833
(17%) did not have a documented asthma history, environmental or medication allergy, and 237
(1%) presented with all three-asthma history, environmental and medication allergies. Patients
with both an asthma history and environmental allergy represented a very small percentage of
total patients encountered (51; <1%), although they did have the youngest median age and IQR
(27 years of age, 16-41). A breakdown by age from Northwell Center for EMS run statistics is
contained in Table 2.2.
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Table 2.1-Patient History by Gender and Median Age with IQR. *.
Median
Characteristic
Total n (%) Female n (%) Male n (%)
Age
IQR
No History
3833 (17)
1729 (8)
2104 (9)
56
33-74
Asthma Only
258 (1)
142 (1)
116 (0)
46
27-61
Environmental Allergy Only
239 (1)
108 (0)
131 (1)
44
25-70
Medication Allergy Only
15461 (69)
7663 (34)
7798 (35)
59
37-75
Asthma and Environmental Allergy
51 (0)
27 (0)
24 (0)
27
16-41
Asthma and Medication Allergy
1188 (5)
702 (3)
486 (2)
47
29-63
Environmental and Medication
1056 (5)
599 (3)
457 (2)
56
33-72
Allergy
Asthma, Environmental and
237 (1)
154 (1)
83 (0)
44
24-59
Medication Allergy
Overall
22371 (100)
11124 (50)
11199 (50)
57
35-74
Missing, Unknown, Non-Binary
1306 (6)
*
*
61
36-76
Gender
Missing Age
658 (3)
33 (0)
72 (0)
*
*
*- 658 cases had no documented age and 1258 cases where a gender was not documented. A total of 48 patients
identified as unknown or non-binary.

Table 2.2-Northwell Center for EMS Run Statistics for 01/01/2018 through 12/21/2019.

Incidents excluded from analysis due to a major roadway, bridge crossing, or highway
intersections were analyzed separately to determine potential impact on the overall data (Table
2.3). The number of incidents excluded from the analysis did not appear significant and
accounted for less than one percent of the entire data set (0.66%). History and gender of the
excluded group appeared consistent with the overall group, although the median age appeared to
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be younger than the overall data set (median age=39.5; IQR 28-55). Also, the percentage of
females in the excluded group was slightly higher than males, but this result was not significant
(54% vs. 46%). Due to the nature of these unique locations, and how the dispatching system
assigns the incidents, it necessitated the exclusion of these incidents as to not manifest artificial
hot spots in the spatial analysis.
Table 2.3-Excluded Incidents Patient History by Gender and Median age with IQR.
Characteristic
No History
Asthma Only
Environmental Allergy Only
Medication Allergy Only
Asthma and Environmental Allergy
Asthma and Medication Allergy
Environmental and Medication Allergy
Asthma, Environmental and Medication Allergy
Overall
Missing, Unknown, Non-Binary Gender
Missing Age

Total n (%)
31 (20)
*
*
112 (71)
1 (1)
4 (3)
7 (4)
2 (1)
157 (100)
10 (6)
2 (1)

Female
n (%)
18 (12)
*
*
57 (36)
1 (1)
4 (3)
4 (3)
1 (1)
85 (54)
*
*

Male
n (%)
13 (8)
*
*
55 (35)
0 (0)
0 (0)
3 (2)
1 (1)
72 (46)
*
*

Median
Age
41
*
*
38.5
67
35
43
46
39.5
*
*

IQR
26-48
*
*
28-58.5
67
25.5-43.5
26-60
33-59
28-55
*
8

Figure 1 displays the point data used for analysis (N=23,462). It should be noted that
units depicted in yellow, in addition to the periodically deployed enhancement units, are
responsible for data displayed and does not reflect the total number of incidents that occurred in
Staten Island from January 1st, 2018 through December 31st, 2019. The unit locations indicated
in “orange” are those participating from facilities or agencies not of Northwell Health, including
the Fire Department City of New York and other voluntary hospitals.
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Figure 2.1-Northwell Health EMS Unit Location and Incident Location Point Data. Borough hospital
locations and other EMS unit cross-street locations are also indicated
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Kernel density estimates for incidents where the patient had a history of asthma (Figure
4), environmental allergies (Figure 5), or both asthma and environmental allergy histories
(Figure 6). Results of the cluster analysis, based on a Bernoulli model that compared cases to
controls by census tract, appear in Table 2.4 (Appendix-H). Figures 7, 8, and 9 are choropleth
maps of the census tract clusters presented in Table 2.4. A qualitative assessment of population
counts and densities, hydrography, and greenspaces are presented in Table 2.5.

Figure 2.4-Asthma History Incidents search radius 1000m, predicted counts per cell.
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Figure 2.5-Environmental Allergy History Incidents search radius 1000m, predicted counts per cell.

Figure 2.6-Asthma and Environmental Allergy History Incidents search radius 1000m, predicted counts
per cell.
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Figure 2.7 Census Tracts with Significant Asthma History (Low/High)

Figure 2.8-Census Tract Clusters with Significant Environmental Allergy History (Low/High)
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Figure 2.9-Census Tract Clusters with Significant Asthma and Environmental Allergy History
(Low/High)

Table 2.5-Significant Census Tracts and General Characterizations of Population counts, and
densities, green spaces, and hydrography based upon geographical representation.
Tract Codes

Cluster

Rel_Risk

Pop_Density

Pop_Count

Green Space

Hydrography

Total
Incidents

% No
Hx

Asthma Hx
279
208.03
29
74
114.01

Low
Low
High
High
High

0.5487
0.6234
1.5793
1.2645
1.5599

Low
Low-Moderate
Moderate-High
Moderate-High
Moderate

Low
Moderate-High
High
Moderate-High
Moderate-Low

High
Moderate
Low
Low
Moderate

Moderate
Low-Moderate
None
Low
Low

186
291
317
564
737

18%
17%
17%
19%
14%

Environmental
Allergy Hx
74
208.01
228
70

Low
Low
Low
High

0.4814
0.6960
0.7153
1.5386

Moderate-High
Low-Moderate
Low
Low-Moderate

Moderate-High
High
Low
High

Low
Moderate
High
Moderate

Low
Low
High
Moderate

23
564
619
1747

26%
19%
18%
14%

Asthma &
Environmental
Allergy Hx
198
208.01
112.01
70
114.01
323

Low
Low
High
High
High
High

0.3347
0.3786
2.1180
2.3636
2.9814
3.0291

Low
Low-Moderate
Low-Moderate
Low-Moderate
Moderate
Low

Moderate-High
High
Moderate-High
High
Moderate-Low
Low

Moderate
Moderate
Low-Moderate
Moderate
Moderate
Low-Moderate

Moderate-High
Low
Moderate
Moderate
Low
Moderate-High

881
330
619
1747
737
16

17%
17%
18%
14%
14%
6%
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New York City Housing Authority (NYCHA) Location Analyses
After initial clustering analysis and review, a preliminary sub-analysis of NYCHA
locations was performed and results are contained in Tables 2.6 and 2.7 below.
Table 2.6-Gender and Age Characteristics (NYCHA) of the patient incidents at influencing the asthma
prevalence at the housing complex locations.
Median
Complex
IQR
Age
Berry (114.01)
50
26-64
Stapleton (29)
35
22-53.5

Male
n (%)
116 (32)
129 (44)

Median
Age
51
36

IQR
24-62.5
22-59

Female
n (%)
252 (68)
165 (56)

Median
Age
50
34

IQR
27-64
23-49

Table 2.7-Incident Review of NYCHA Complexes and Census Tracts, in relation to overall
responses. *
CT Asthma Loc_Count Loc_Asthma
CT Count
Delta
Location (CT)
n (%)
n (%)
n (%)
Berry (114.01)
746
94 (13)
375 (50)
72 (19)
7%
Cassidy -Lafayette (81)
63
7 (11)
9 (14)
1 (11)
0%
Mariner's Harbor (319.01)
53
12 (23)
31 (58)
7 (23)
0%
New Lane (6)
255
15 (6)
122 (48)
10 (8)
2%
Richmond Terrace (7/81)
98
16 (16)
20 (20)
5 (25)
9%
South Beach (64)
677
88 (13)
323 (48)
56 (17)
4%
Stapleton (29)
312
60 (19)
133 (43)
38 (29)
9%
Todt Hill (173)
69
5 (7)
47 (68)
3 (6)
-1%
West Brighton 1 & 2 (133.01)
27
7 (26)
27 (100)
7 (26)
0%
* CT-Census tract and Loc refers to the assignments at the location. Delta is the difference in asthma
rates between location and census tract.

Individual Census Tract Evaluation
Additionally, it became necessary to investigate the results of the initial clustering
analysis for areas indicating potential high intensity locations. We conducted a “hotspot within a
hotspot” analysis by applying local kernel density estimation, based upon the confirmed location
of incidents where the patients had an asthma history, environmental allergy history, and both
asthma and environmental allergy histories. Local hot spot kernel density estimates and point
data are presented below (Figure 10, 11 and 12).

75

Figure 2.10-Hotspot Identification KDE Counts-Asthma History
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Figure 2.11-Hotspot Identification KDE Counts-Environmental Allergy History
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Figure 2.12-Hotspot Identification KDE Counts-Asthma & Environmental Allergy History

Discussion
It is important to discuss what these data do, and do not, represent. It should be clearly
understood that by using data from patients who were treated and/or transported by ambulance
clearly indicate that this is a “sick” population and does not necessarily reflect the overall health
of the population within the borough. There is not necessarily a correlation between the patient’s
history and the reason they may have called for an ambulance (e.g., chest pains and asthma
history, or motor vehicle collision and allergy history). It should also be noted that pediatric
patients reflect a relatively small percentage of patients encountered by EMS (6.1%) (Table 2.2),
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although the United States Census Bureau estimates that under 18 population is approximately
22 percent in the borough.
In Figure 1, the displayed map indicates the cross-street locations of the ambulances
within the borough. Additional units may be deployed to augment the units identified when call
volume or seasonal issues arise. The units in “yellow” are those directly linked to the point data
on the map and are also deployed from the nearest hospital location to their designated crossstreet location. The units in “orange” are units that are deployed from other voluntary hospital
locations, or from nearby municipal EMS stations run by the Fire Department City of New York.
Although the heaviest volume of incidents is in the nearby vicinity of the units, the point data
clearly indicates that responses may be borough-wide and in every census tract under analysis.
The highest intensity KDE count locations presented in figure 2.4, figure 2.5 and figure
2.6 seem to coincide with the higher population counts and densities displayed in figures 2.2 and
figure 2.3 (Appendix-G). However, there does appear to be locally high intensity locations that
may be inconsistent with population count or density that bear further investigation in both
southwest shoreline (Tottenville) and the inland area off the south shore (Todt Hill).
A review of geographical characteristics reveals that census tracts with low to moderate
green spaces and hydrography, and moderate to high population counts and population density,
tend to have higher relative risk estimates for asthma history (Table 2.5). It can also be noted
that census tracts with moderate amounts of green spaces and hydrography, and low to moderate
population density, tend to have higher relative risk for environmental allergy history and both
asthma and environmental allergy history. Although statistically significant, the Travis (Fresh
Kills Park) and Arlington (Mariner’s Harbor) locations should be viewed with skepticism and as
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outliers due to the extremely low population counts and density, as well as the limited number of
overall incidents observed in those census tracts.
New York City Housing Authority (NYCHA) Locations and Asthma
Two census tracts seem to be heavily influenced by the presence of NYCHA housing
locations within the area borders, Dongan Hills (Berry) and Rosebank (Stapleton). At the
Dongan Hills location, the housing complex accounts for 50% (n=375) of the total incidents, and
the Rosebank complex accounts for 43% (n=133) of the total incidents, within the census tract.
Table 2.6 details the age and gender distribution at these locations, and one can discern a
substantially younger population with asthma history at the Rosebank (Stapleton) housing
complex, as well as higher percentage of female patients at both locations.
NYCHA locations are responsible for approximately 4% (n=961) of the total incidents
handled by the EMS agency across all of Staten Island. Table 2.7 contains an incident review of
census tracts containing the NYCHA complexes. The two NYCHA locations identified within
the census tracts of concern have a higher percentage of incidents with asthma histories, more
than 5% point higher. The Richmond Terrace complex also presents with a higher percentage of
incidents with asthma; however, this location straddles two adjacent census tracts, making
identification problematic. The location also accounts for less of the total responses in the area
as compared to the Stapleton and Berry Complexes (20% vs. 43% and 50%, respectively). The
New Lane location is a relatively recent addition in the area and was not represented well
geographically for analysis. A nearby location was used that could be identified within the same
census tract and adjacent to the location.
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Hotspot Asthma Location (Arrochar)
The Arrochar hotspot location (CT-74) was a unique location to evaluate, as it was an
indicated cold spot for environmental allergy history, yet an identified hotspot for asthma history
patients (RR 1.2645; p=0.0039). A cluster of six locations was identified that influenced the
results, which included two low-income apartment complexes, a senior assisted living building, a
transitional housing location, a cross street location, and single residence.
Hotspot/Cold Spot Environmental Allergy Census Tracts (South Beach)
In Figure 9, we identify an area of high relative risk directly adjacent to a census tract that
has low relative risk. This gives the impression that the selection of a census tract as the area of
aggregation might have unduly influenced the results of the analysis. Therefore, we conducted
another hotspot within hotspot analysis by combining the census tracts and incidents to
investigate a potential reason contributing to the results. A kernel density analysis of the area
revealed a singular hotspot within the area contributing to the high relative risk (Figure 11). This
singular location was responsible for an extremely large number of incidents, which also had a
very large number of patients with environmental allergies (n=531, 19%). The remainder of the
area, including the adjacent census tract, did not reveal any additional hotspots and had a
consistent KDE count contour.
Hotspot Identification Asthma and Environmental Allergy History Incidents (South Beach II)
The elevated relative risk seen in the Stapleton (Asthma) and South Beach
(Environmental Allergy) are present in the analysis of incidents involving patients with asthma
and environmental allergy histories, as well as the influencing sources. The Mariner’s Harbor
census tract, with the highest calculated relative risk, must be interpreted cautiously due to the
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low count in overall incidents used for analysis, as well as the low population count and density.
The remaining census tract of elevated relative risk is census tract 112.01, located in the South
Beach area. A local hotspot analysis identified several areas influencing the results (Figure 14).
In an area nearby the regional hospital, two (2) ancillary medical facilities and a public
elementary school have a substantial number of associated incidents. A cross street location near
a local fishing pier and beach also appears to be a common location for events. A single
residential location had frequent requests for EMS that created a local hotspot.
Cold Spot Asthma and Allergy History Census Tracts
Census tracts 208.03 (Rossville-Woodrow) and 279 (Lighthouse Hill) are substantially
low relative risk areas with respect to asthma history. Lighthouse Hill may be explained due to
the limited number of incidents in an area that is low in both population count and density, and a
large amount of green space (1,051 acres) and hydrography (157 acres). The RossvilleWoodrow location has a low-to-moderate population density, with a moderate-to-high
population count, and a relatively high green space (147 acres) and hydrography (6.3 acres). As
a percentage of total acreage, green spaces account for approximately 28% and 78% of the
Rossville-Woodrow and Lighthouse Hill census tracts, respectively. In comparison, none of the
hotspot locations had green space amounts above 18% of the total acreage.
There is substantial debate as to whether the “greening” of the urban environment
facilitates a decrease in the prevalence of asthma.23 The proposition that green spaces help
remove pollutants has not been clearly demonstrated, and in some cases heavy green density is
associated with elevated pollutant levels. The mere presence of a green space may not be as
important as to what types of flora comprise the vegetation, how it is positioned and what
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“threshold” is required to achieve significant health benefits.24-26 Further in-depth
epidemiological research, using full incident data for the region, and comparing to green space
composition and percentage, is required to produce evidence to help answer these questions.27
The census tracts with the low relative risks are displayed in Figure 9. As was explained
earlier, the Arrochar (CT 74) location appears be an artifact due to an area of aggregation
directly adjacent to an area hotspot. The New Springville tract (CT 228) is an area of extremely
low population and density, had a small number of incidents occur within the tract, and is the
location of the Fresh Kills Park and William T Davis Wildlife Refuge. The only area of note is
the Rossville-Woodrow tract (CT 208.1), which is an area of low-to-moderate population
density. There are 182 acres (28%) and 3 acres (0.5%) of green space and hydrography,
respectively, located within this tract.
It has been suggested the overall prevalence of allergic sensitization does not vary across
US census regions, except in early life; and allergen-specific sensitization differs based on
sociodemographic and regional factors.28 CT 208.1 seems to be a contradiction since it has
similar population count and density, hydrography, and nearby green spaces like other census
tracks that have unremarkable relative risk. There may be regional variation of allergens and
allergen types based upon national regions; however, local exposures should be similar based
upon socio-demographic characteristics. Although this could be an artifact secondary to units
operating in the nearby vicinity, it is considered highly unlikely since the incidents are not
assigned to the units based upon allergy history. There is also a possibility of inaccurate
documentation of environmental allergy history, but that is also considered unlikely as it would
have to been differential to this census tract. A nearby influencing hotspot could not be detected.
Further investigation of the underlying characteristics and plant and animal species distribution
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of this census tract might be enlightening but is beyond the scope of this research and available
data.
Rationale for Prioritization of Environmental Allergy History
An analysis of patients with a documented medication allergy history was initially
intended in the study design. However, initial data review indicated that 69% of the patients
encountered had a documented medication allergy. This finding gave pause since medication
allergies in the general population should be closer to 1 in 100, according to the World Allergy
Organization.29 Further investigation found that the documentation of medication allergies is
being conflated with adverse drug reactions (ADRs), which are commonly misunderstood by the
patient, and not further investigated by the EMS provider. This situation is formidably grounded
by the health care providers failing to maintain the patient’s medication records to discriminate
between types of ADRs, or educating the patient on the drug reaction, leading to a propagation of
unreliable information.30 This could have profoundly dangerous consequences for the patient.31
The World Health Organization (WHO) defines an ADR as “….any noxious, unintended,
and undesired effects of a drug that occurs at doses used for prevention, diagnosis, or
treatment”.32 An ADR may be categorized as either predictable (type A) or unpredictable (type
B), with type A accounting for 80% of all adverse reactions. This includes overdoses, side
effects, secondary effects, and drug to drug interactions. Type B adverse reactions include drug
intolerance, idiosyncrasy, pseudo-allergic reactions, and allergic reactions.
The WAO defines a “drug allergy” as an immunologically mediated drug
hypersensitivity reaction, which may be IgE or non-IgE mediated.33 The true incidence of drug
allergy is not known and is difficult to determine with the intermingling of causes within overall
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adverse drug reactions. However, the American Academy of Allergy, Asthma, and Immunology
estimates that true drug hypersensitivity reactions only account for 5-10% of those categorized as
adverse drug reactions.34, 35 Since it was not possible to discern true medications allergies within
this cohort, and it was unlikely the EMS providers questioned the patient as to what signs and
symptoms occur when taking the offending medication, it was determined that an analysis of any
value would be well beyond the scope of this study and be more appropriate for a prospective
intervention analysis. However, recommendations for improving the patient questioning and
documentation of medication adverse reactions can still be promoted to reduce the possibility of
poor health outcomes.
Limitations
There are several limitations to this study, the most notable being the use of data not
specifically created or optimally structured for the project. However, this is also a strength in
that data obtained from a regional resource can be used to identify areas of concern for potential
intervention. The accuracy of the recorded data might be compromised as some patients may be
poor historians and not report all their allergies. Similarly, some providers may not be diligent
about obtaining an allergy or asthma history and fail to document relevant findings. The use of
this agency’s data allowed for a broad overview of the population that would not be found
through an individual hospital location. Additional limitations include technological constraints
of the GIS data and layers used for analysis leading to incorrect incident locations, and the use of
census tracts as the unit of aggregation, which can have considerable variation in terms of size
and population. However, the use of census tracts was deemed reasonable since further research
could utilize available tract level demographic, housing, social and economic profiles. Census
tracts also represent a defined unit for targeting government resources and interventions.
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Conclusion
Overall, there is a general association between asthma and environmental allergy clusters,
with elevated and reduced relative risk occurring in the same geographic areas. Despite the
limitations, this study was able to contribute to the field in several ways. Firstly, specific hot
spot locations for patients with asthma histories were identified for potential intervention,
including two (2) NYCHA complexes. It is not implied or stated that the patients transported by
the EMS agency were suffering from asthma at the time of transport; however, it can be inferred
that a substantially sick population being transported by ambulance might be representative of an
overall population that might be adversely impacted by asthma and interventions undertaken to
investigate and improve the overall health of that population.
Secondly, this study was able to identify a hotspot for patients with environmental allergy
history that was unduly influencing the overall results of the analysis. This location was later
identified as a mental health facility responsible for 501 incidents over a 2-year period.
Additionally, we were able to identify a unique area of low relative risk that seems to contradict
evidence of consistency of allergy sensitization across census tracts. Further investigation may
prove enlightening to the increasing prevalence of allergic diseases.
Lastly, the study was able to identify a structural issue with data as it is related to
medication allergy. This has potentially profound consequences to overall patient care in both
the hospital and pre-hospital settings. The failure of the provider in discriminating a medication
allergy from the overall category of adverse drug reactions (ADRs), and the lack of educating the
patient as to the differences, may lead to the patient being denied appropriate treatment for a
medical condition. A relatively benign adverse effect such as gastrointestinal discomfort from
aspirin might be construed as an allergy and the patient may subsequently be denied treatment in
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the setting of suspected myocardial infarction, where it has been demonstrated to decrease
morbidity and mortality. Medical providers from all areas of practice must question the patient
about the undesired effect before classifying the reaction as allergy.
Research using prehospital data should be considered when a broad overview of an area
might provide a different perspective of a disease condition. In addition, supplemental research
should be conducted with additional data obtained from other EMS agencies within the borough
to confirm or refute the findings of this single agency.
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CHAPTER 4 – INITIAL DEVELOPMENT
EFFORTS OF ALGORITHM FOR APPLICATION
ON PREHOSPITAL DATA TO IDENTIFY
POTENTIAL MISSED CASES OF ALLERGY
AND/OR ANAPHYLAXIS
Abstract
Background: Emergency medical services (EMS) providers are taught a very structured
methodology in their approach to a patient. Because of closely following this structured
approach, prehospital emergency care providers do not easily discern the signs and symptoms of
complex disease processes like anaphylaxis as they move through the various stages of the
patient assessment. We propose the development and modeling of an algorithm, based upon
existing patient record data, to identify cases of anaphylaxis from prehospital based data
elements.
Methods: Initial review of incidents from 2018-2019, based upon the NIAID/FAAN criteria, and
then matched against emergency department admissions/discharge diagnosis to determine if any
additional cases of allergy and/or anaphylaxis be discovered. This process would then be followed
by an in-depth analysis of the cases to find any commonality in signs and symptoms, or alternative
provider impressions, linked to an accurate prehospital diagnosis of allergic reaction or
anaphylaxis. If identified, a modified application of the NIAID/FAAN criteria could serve as a
basis of a model on alternative data
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Results: A total of 222,681 records are available to be analyzed for this study. Only cases
transported to Northwell Health System facilities, where patients were 18 years or older were
further considered for additional inquiry (n=111,127, 49.9%). Screen based upon NIAID/FAAN
anaphylaxis diagnostic criteria, identified additional 4 cases over an 8-month retrospective
review. Using a retrospective hospital records review, an additional ten (10) cases of allergy or
anaphylaxis were identified over a one-month period.
Conclusions: Results did not reveal any significant commonalities in which to inform the model
for application. Inaccuracy in anaphylaxis diagnosis in both hospital and prehospital environments
make consistent identification of patients difficult, and development of an algorithm or model for
application premature. Improved provider education, and a change of approach to allergy history
assessment, may be a better approach.
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Introduction
Emergency medical services (EMS) providers are taught a very structured methodology
in their approach to a patient.1 Although there may be substantial deviation from this practice in
the field, the basic structured approach is taught to all basic and advanced providers. The
patient assessment approach involves initial scene size-up, a primary survey, history taking, a
secondary assessment, and then re-assessment of the patient. The primary survey involves a
rapid evaluation of the patient for immediate life threats, and actions by the provider to halt or
reduce the untoward effects of discovered pathophysiological manifestations. It is not until the
provider moves past the primary assessment phase, and into history taking, that first questioning
of the patient’s allergy status is attempted during a review of their past medical history. This
questioning is a mere rudimentary attempt to determine the existence of an allergy history, what
is (are) the inciting allergen(s), and the potential allergic response to the allergen. Once the
provider reaches the secondary assessment phase, they can evaluate the patient’s entire body, and
review systems. Because of closely following this structured approach, prehospital emergency
care providers do not easily discern the signs and symptoms of complex disease processes like
anaphylaxis as they move through the various stages of the patient assessment.
The National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with
the Food Allergy and Anaphylaxis Network (FAAN), developed diagnostic criteria to aid
medical practitioners in identifying anaphylaxis.2 A concept map of the diagnostic criteria
indicates there are multiple pathways to both a negative and positive anaphylaxis diagnosis
(Figure 3.1). Therefore, a potential opportunity exists to integrate an algorithm into the process
to assess the patient for an allergic response that has, or potentially will, progress to lifethreatening anaphylaxis.
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There have been several validated methods for identifying anaphylaxis, anaphylactic
shock, and angioneurotic edema.3-9 However, these methods are based on administrative and
claims data that have identified physician diagnoses. Unfortunately, EMS agency records are
based upon the National Emergency Medical Services Information System data elements, which
are independent of the International Classification of Diseases (ICD).10 A patients identified
signs, symptoms, and provider impressions are used to assign a generalized ICD 9 or 10 code for
the purposes of billing. The code may be assigned based upon the condition at the time of
arrival, later with a physicians diagnosis, or by code “799.9 Unspecified Illness”.11 As a result,
the code generated for billing will in high probability not be consistent with anaphylaxis.
Therefore, a different method for case identification needs to be applied to EMS data.
We propose the development and modeling of an algorithm, based upon existing patient
record data, as a beginning step toward that goal. It is proposed that this be achieved by an
initial review of incidents from 2018-2019, based upon the NIAID/FAAN criteria, and then
matched against emergency department admissions/discharge diagnosis to determine if any
additional cases of allergy and/or anaphylaxis be discovered. This process would then be
followed by an in-depth analysis of the cases to find any commonality in signs and symptoms, or
alternative provider impressions, linked to an accurate prehospital diagnosis of allergic reaction
or anaphylaxis. If identified, a modified application of the NIAID/FAAN criteria could serve as
a basis of a model on alternative data.
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Figure 3.1 Concept Mapping of NIAID/FAAN Anaphylaxis Diagnostic Criteria
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Methods
Study Design
This will be a retrospective analysis of patient record data collected from January 1st,
2018 through December 31st, 2019. Both institutional review boards of the City University of
New York and the Northwell Health System approved this study with a waiver of informed
consent.
Setting
Data will be obtained from the Emergency Medical Services (EMS) transports of the
Northwell Health System ambulance service operating inside the boundaries of the city of New
York, and within the municipal 911 system dispatched by the Fire Department of the City of
New York (FDNY). The Regional EMS Council (REMSCO) and Regional EMS Medical
Advisory Committee (REMAC) establish protocols for EMS care under the oversight of the New
York State Department of Health, and with approval of the legislative authority of the New York
State EMS Council (SEMSCO) and Medical Advisory Committee (SEMAC), as delineated
under Article 30 of the New York State Public Health Law (PHL Article 30 §3002, §3002-a,
§3003, §3003-b).12 The EMS agency operates ambulances in the 911 system as a voluntary
participating, hospital-based agency under contract with the City of New York. Ambulances are
regionally deployed within the boroughs of Queens, Manhattan, and Staten Island, but may be
re-deployed anywhere within the confines of the City of New York, at the direction of the Fire
Department City of New York Communications Center. For the purposes of this study, the
patient records of the Northwell Health, Center for EMS NYC 911 Division ambulance
responses and hospital admission/discharge data are being examined.
97

Data
Only cases where patients 18 years or older, transported to Northwell Health facilities,
were used for this study. The prehospital database HealthEMS (Stryker Corp, Kalamazoo, MI)
was queried to identify actual and potential cases of allergy and/or anaphylaxis where onset of
illness was less than twenty-four (24) hours. Interfacility transports were excluded, as the
management of the patient would have been determined by the sending and/or receiving facility
physicians’ assessment and management, and not solely determined by the EMS provider.
The EMS divisions and hospital facilities where records were accessed is included in the
table below (Table 3.1).
Table 3.1-Northwell EMS NYC Divisions and Hospital Facilities
Northwell EMS Divisions
Northwell Facilities
NYC 911-Staten Island
Lenox Health Greenwich Village
NYC 911-Lenox Hill
Lenox Hill Hospital
NYC 911-Queens & Manhattan
Long Island Jewish Medical Center
Cohen Children's Medical Center
Staten Island University Hospital - South
Staten Island University Hospital - North
Long Island Jewish Valley Stream (Franklin)
Long Island Jewish Forest Hills (Forest Hills Hospital)
North Shore University Hospital

Variables
In addition to patient age and gender, additional criteria were used to create the screening
tool for this study. The search criteria variables are listed in the table below.
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Table 3.2-Search Criteria Variables available within the electronic medical
records used by the Center for EMS.
Characteristic
History

Mucosocutaneous

Airway

Breathing-Quality

Breathing-Lung Sounds
Provider Impression-Respiratory
Provider Impression-Cardiovascular

Provider Impression-Gastrointestinal

Provider Impression
Vital Signs

Type
Medication Allergy
Environmental Allergy
Cardiac
Diabetic
Pale
Flushed
Erythema
Swollen
Rash
Diaphoretic
Moist
Hives
Itchy
Fully Obstructed
Partially Obstructed
Difficulty Swallowing
Drooling
Stridor
Labored
Slow
Rapid
Diminished
Wheezes
Dyspnea-SOB
Hyperventilation
Altered Level of Consciousness
Cardiac Symptoms
Chest Pain
Dizziness
Syncope/Fainting
Unconsciousness
Abdominal Pain
GI-Diarrhea
Nausea
Vomiting
Allergic Reaction
Systolic Blood Pressure < 90 mmHg
Pulse Oximetry (SPO2 < 94)
Respiratory Rate > 24 per minute

Methods of Inquiry
Initial query of the database was used to identify cases with the signs, symptoms, and
provider impressions listed in Table 3.2. Various tables were then entered into Microsoft Access
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where queries of the tables could be created that are consistent with allergy or the National
Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network
(NIAID/FAAN) criteria for anaphylaxis (Figure 3.2). Once the cases were identified they were
linked with patient demographic information from which the patients admitting/discharge
diagnosis could be obtained from in-hospital electronic medical records.
Figure 3.2-NIAID/FAAN Diagnostic Criteria for Anaphylaxis

Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson Jr, N. F., Bock, S. A., Branum, A.,
... & Decker, W. W. (2006). Second symposium on the definition and management of anaphylaxis:
summary report—Second National Institute of Allergy

Search criteria variables were used to create secondary variables identifying specific
systems cases (Table 3.3). The secondary variables were then combined in a manner to be
consistent with NIAID/FAAN criteria (Table 3.4). It should be noted that, due to the structure of
the secondary variables and the combining of systems to identify potential anaphylaxis cases,
cases identified through the III criteria were also captured in the II criteria (i.e.-SBP <90 mmHg).
However, the possibility of a low blood pressure without any other signs and symptoms of other
system involvement still exists. Therefore, it was left in the screening tool. Query runs were
conducted for a 1-month, 2-month, and then for a 5-month interval in 2018.
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Table 3.3-Secondary Variable Creation *
Secondary Variable
Mucosocutaneous Case

Category
Skin/Mucosal

Sub-Variables
Pale
Flushed
Erythema
Swollen
Rash
Diaphoretic
Moist
Hives
Itchy
Airway
Fully Obstructed
Partially Obstructed
Difficulty Swallowing
Drooling
Stridor
Cardiovascular Case
Cardiovascular Impressions Altered Level of Consciousness
Cardiac Symptoms
Chest Pains
Dizziness
Syncope/Fainting
Unconscious
Vital Signs
Systolic Blood Pressure < 90 mmHg
Respiratory Case
Respiratory Impressions
Dyspnea-SOB
Hyperventilation
Signs and Symptoms
Labored
Slow
Rapid
Diminished
Wheezes
Vital Signs
Pulse Oximetry (SPO2 < 94)
Respiratory Rate > 24 per minute
Gastrointestinal Case
GI Impressions
Abdominal Pain
GI-Diarrhea
Nausea
Vomiting
Allergic Reaction Case
Impressions
Allergic Reaction
*-Case is identified if one or more of the sub-variables is positively identified in the prehospital EMR.
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Table 3.4-Anaphylaxis Case Identification through a query of cases meeting
the NIAID/FAAN criteria.
NIAID/FAAN Criteria
I

II

Variable
Mucosocutaneous Case
Cardiovascular Case
Respiratory Case
Environmental Allergy History
Medication Allergy History
Cardiovascular Case
Respiratory Case
Cardiovascular Case
Gastrointestinal Case
Cardiovascular Case
Mucosocutaneous Case
Respiratory Case
Gastrointestinal Case
Respiratory Case
Mucosocutaneous Case
Gastrointestinal Case
Mucosocutaneous Case

III

Environmental Allergy History
Medication Allergy History

Linkage
AND
OR

OR
AND
AND
OR
AND
OR
AND
OR
AND
OR
AND
OR
AND

OR
AND

Systolic Blood Pressure < 90 mmHg

Results
A total of 222,681 records are available to be analyzed for this study, 108,561 from 2018,
and 114,120 from 2019 (Table 3.4). Of the 222,681 records, 131,054 patients were transported
to hospitals (58.9%). Of the total patients transported, we specifically identified only cases
transported to Northwell Health System facilities where it was possible to access electronic
medical records for admitting or discharge diagnosis and potential decision making (n=115,270;
51.7%). Only cases where patients 18 years or older were used for this preliminary
investigation (n=111,127; 49.9%).
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Table 3.4-Overall Incidents responded to by the Center for EMS over the study period.

The cases identified for each NIAID/FAAN criterion are in the Table 3.5.
Table 3.5-Preliminary Data Runs based upon identified cases presented as n (%).
Query Dates
January 2018
February-March
2018
April-August
2018

Total Cases
Transported
622

NIAID
#1
54 (9)

NIAID
#2
24 (4)

NIAID
#3
5 (1)

NIAID
Met
66 (11)

PI Allergy
Meet
4 (1)

Extra
Cases
2

Asthma
Cases
2

1218

86 (7)

38 (3)

9 (7)

103 (8)

7 (1)

0

5

4463

255 (6)

122 (3)

37 (8)

327 (7)

11 (0)

2

8
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Patient Records Identified Through Emergency Department Diagnosis
One month of transport data was matched to hospital diagnosis information obtained
through the health system’s electronic medical records system. August 2019 was selected based
upon previous research indicating that August has a higher frequency of allergic reaction cases
per month over the entire research period. Of the 2896 identified patient transports to Northwell
Health system facilities, approximately 8.7% (n=252) were not able to be matched to hospital
charts. Patients who could not be matched were higher percentage male than the overall group
of transports; however, the average and median age were similar between the two groups. 21
cases of allergic reaction or anaphylaxis were identified from the matched cases (0.79%) (Table
3.6). Of the 21 cases, there were more females than males (12 vs 9) and a provider impression of
allergic reaction was only documented in 52% of the cases (n=11).
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Table 3.6-Allergy and Anaphylaxis Cases Identified through Hospital Records review of all Northwell transport cases to Northwell facilities in
August 2019.
Case

Gender

Age

Provider Impression #1

Provider Impression #2

1

Female

46

Abdominal Pain

2

Female

27

Abdominal Pain

Dizziness

3

Female

59

Abdominal Pain

Nausea

4

Male

61

Alcohol Intox

Behavioral Disorder

5

Male

19

Allergic Reaction

6

Male

47

Allergic Reaction

7

Female

19

Allergic Reaction

8

Female

18

Allergic Reaction

9

Female

36

Allergic Reaction

10

Male

47

Allergic Reaction

11

Female

34

Allergic Reaction

12

Female

69

Allergic Reaction

13

Female

30

Allergic Reaction

14

Male

33

Allergic Reaction

15

Male

47

Dyspnea-SOB

16

Female

38

No Medical Problem

17

Male

76

Skin Condition

18

Female

28

Unknown

19

Female

68

Weakness

20

Male

48

Weakness

21

Male

26

Weakness

Provider Impression #3

Provider Impression #4

Vomiting

Diarrhea

Monitoring Required
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Discussion
Anaphylaxis Diagnosis with NIAID/FAAN Criteria
In previous research, NIAID/FAAN anaphylaxis criteria (Figure 3.1) has been retrospectively evaluated
and found to be 96.7% sensitive and 82.4% specific for anaphylaxis (PPV 68.6%, NPV 98.4%).13 It has also
been prospectively evaluated and found to be 95.1% sensitive and 70.8% specific for anaphylaxis (PPV 63.7%,
NPV 96.4%).14 Although these results indicate an effective diagnostic criterion for anaphylaxis, they do not
speak to the complexities of the actual diagnosis in practice. As was previously introduced, a concept map of
the diagnostic criteria indicates there are multiple pathways to both a negative and positive anaphylaxis
diagnosis (Figure 3.2). For example, a patient with a history of allergies that was not exposed to a known or
likely allergen could still reach a diagnosis of anaphylaxis through an alternative pathway if they had
mucosocutaneous signs and symptoms with either cardiovascular or respiratory system involvement, which is
not necessarily obvious by looking at the listed criteria. Likewise, a patient with an exposure to a known
allergen without a low blood pressure could still be diagnosed with anaphylaxis if presenting with two (2) or
more body system involvement.
Although the diagnostic criteria are independent of the sign or symptom severity, provider impression of
the severity seemed to more greatly influence whether the patient was treated with epinephrine or received a
discharge/admission diagnosis of anaphylaxis.15, 16 The existence of certain signs and symptoms might indicate
multiple system involvement regardless of perceived severity. For example, patient presentation with audible
stridor could indicate both mucosocutaneous sign and respiratory system involvement warranting immediate
treatment regardless of allergy history. Pale, moist, and/or diaphoretic skin would be considered
mucosocutaneous signs but are also evident indicators of shock and cardiovascular involvement. Multiple body
system involvement in the setting of a known or likely allergen exposure, or multiple body system involvement
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including mucosocutaneous signs and symptoms without an exposure, are the hallmarks of an anaphylaxis
diagnosis, not the severity of the signs and symptoms.
Initial Case Identification
Unlike previous research identifying anaphylaxis cases from hospital emergency department (ED)
records using International Classification of Diseases Version 9 or 10 diagnostic codes (ICD 9/10), prehospital
electronic records rely on provider impressions to determine patient condition and then assigns generalized ICD
9/10 for the purposes of billing.17 The resulting billing ICD 9/10 code may have very little correlation to the
patient’s actual disease process. Therefore, this project required a new basic framework be developed specific
to the prehospital EMR to help identify any potentially new cases of allergy or anaphylaxis.
The NIAID/FAAN criteria provided a starting point from which to look at the data obtained through the
prehospital records and select the cases that would have the highest probability of being an allergy or
anaphylaxis case. The initial goal was to cast as wide of a net as possible with the initial search parameters to
find outlier cases, while also still being consistent with what prehospital providers would be documenting for
potential cases of allergic reactions. Therefore, all mucosocutaneous signs and symptoms were included in the
initial criteria, although there was a high probability of some signs and symptoms being consistent with other
more likely disease processes. For example, a 53-year-old male patient with pale diaphoretic skin, a history of
cardiac problems and environmental allergies, and hypotension would be identified as a potential anaphylaxis
candidate although a cardiac diagnosis would be more likely. This was considered reasonable in limiting the
number of cases identified for subsequent emergency department diagnosis matching.
As was mentioned in the research from a previous chapter (#2), the documentation of a potential
allergen trigger is not easily obtained without a thorough review of written narratives, which is both time
consuming and inconsistent. However, patient history of either medication or environmental allergy is
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necessary to qualify under criteria II and III and allows us to use that documentation as an over-generalized
proxy for exposure to an allergen. In criteria I, no previous allergy history or trigger allergen is necessary for
the anaphylaxis diagnosis. However, it does rely heavily on the presentation of mucosocutaneous signs and
symptoms with either respiratory or cardiovascular system involvement. As was previously mentioned, the
inclusion of all potential mucosocutaneous signs and symptoms has the potential of also capturing other more
likely disease processes than anaphylaxis.
Findings of Initial Screen
The initial screen of overall incidents for the month of January 2018 was able to identify 2 additional
cases of allergy/anaphylaxis not previously identified by prehospital providers. It also had one case of allergic
reaction identified by the prehospital provider that had a different ED diagnosis. In this case the patient had a
history of allergies, a potential triggering event, and a swollen tongue. However, it was determined the patient
was having another condition that contributed to the swollen tongue that was completely coincidental. The
second screening attempt used assignments for the months of February and March of 2018 did not reveal any
additional cases. However, it did capture all cases of allergic reaction identified by the prehospital providers.
The final screen revealed 11 provider impression cases of allergic reaction and an additional 2 other cases of
allergy/anaphylaxis not identified prehospitally.
Overall, the screening of patients over the age of 18 years of age transported to Northwell facilities using
prehospital EMR data entries was able to identify several allergy and/or anaphylaxis cases. It also indicated that
several patients with allergic reactions or anaphylaxis are being potentially missed prehospitally. Based upon
the limited data obtained by the screens, 20% more patients with allergy or anaphylaxis could be potentially
missed by prehospital providers. This is consistent with what has been identified to be occurring within hospital
emergency departments.18
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Initial Review of Patient Records Identified Through Screen
An initial review of the prehospital records of patients identified through the screening process did not
reveal any significant commonalities in which to inform the model for application. Although most of the cases
identified were done so through the prehospital provider impression of allergic reaction, supplemented by the
additional cases identified through the screen, the signs, symptoms, and provider impressions were too diverse
and inconclusive for modelling purposes. However, based upon this information it was felt that the overall
complexity of allergy presentation and diagnosis of anaphylaxis may not be accurately captured by the
screening process. Therefore, it was decided that an overall approach should be attempted by working
backwards from hospital diagnosis to prehospital presentation.
Initial Review of Patient Records Identified Through Emergency Department Diagnosis
As with the NIAID/FAAN criteria-based screening tool, the hospital-based diagnosis to prehospital
medical record process did not reveal a consistent and common set of provider impressions (other than provider
impression of allergic reaction). However, it did reveal provider impressions not previously considered in the
initial screening tool process (weakness), and higher number of patients with abdominal pain (females) (Table
3.6). It also revealed 10 additional cases of allergy/anaphylaxis as compared to the 4 cases identified through
the initial EMS data screen. This is over twice the estimated cases identified through the initial screening
process and for a single month review.
Hospital Emergency Department Anaphylaxis Diagnostic Accuracy
During the patient chart evaluations, it was discovered the consistency and accuracy of physician-based
discharge/admitting diagnosis may not be properly established for the purposes of this project. The education
and experience of the physicians documenting findings in the charts varies from new residents through senior
attending physicians. There has been substantial evidence developed over the years of the misdiagnosing and
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underdiagnosing of anaphylaxis with a 2010 study showing only 43% of anaphylaxis cases being properly
recorded in the patient chart.19 Additional research has indicated only 49% of food-related, and 69% of venomrelated, anaphylaxis was properly recorded.20, 21
It has been suggested the failure to properly record or identify a diagnosis of anaphylaxis maybe
multifactorial with the main one being inaccurate ICD coding, with an anaphylaxis event being difficult to code,
with milder cases being coded as a reaction.22 Another reason is believed to be the limited time available to
make a correct diagnosis or exclude alternative disorders before discharge or admission from the emergency
department. This also occurs in the prehospital setting with pressure on the providers to have the patient rapidly
treated and transported to the hospital. Finally, the lack of awareness of the spectrum of anaphylaxis and the
diagnosing criteria leads to only cases of anaphylactic shock being diagnosed and charted. To address this,
some institutions have implemented interventions to improve the diagnosing and recording of anaphylaxis.23, 24
The lack of consistent and accurate emergency department diagnosis may adversely affect assessment of
prehospital identification of anaphylaxis. Patients properly identified as having a confirmed exposure to a
known allergen and meeting diagnostic criteria may be “officially” diagnosed in the emergency department as
something other than anaphylaxis and contradicting the use of the hospital diagnosis as a “gold standard”.
However, in the absence of a confirmed known or likely allergen exposure, the emergency department
diagnosis of allergic reaction in conjunction with observed signs and symptoms by EMS, may be a more
accurate method to confirm anaphylaxis in the prehospital environment.
Prehospital Provider Anaphylaxis Diagnostic Accuracy
As with hospital-based anaphylaxis diagnosing and recording, prehospital providers have similar
difficulties.25 As was mentioned in an earlier chapter, EMS providers suspecting a case of anaphylaxis can only
record that information as a provider impression of allergic reaction. Any additional information regarding
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anaphylaxis would be recorded in the narrative section of the electronic medical record. Also, the prehospital
providers may similarly be unaware of the spectrum of anaphylaxis and the diagnosing criteria.15, 26-28
Considering deficiencies in the ability of providers in either the prehospital or hospital arenas to
accurately identify and chart the diagnosis of anaphylaxis, the approach to identify allergic reactions and
anaphylaxis through a modelling of prehospital data may be premature. The advancement of knowledge
through interventions with prehospital providers in both identification and documentation may serve as the
initial starting point of such a goal.
Next Steps
Based upon the limited results obtained from our initial attempts, a bi-directional data gathering effort
needs to be undertaken to get enough information to determine frequency and combinations of various signs and
symptoms of each body system involved in the cases of anaphylaxis. The data must be bi-directional as it
appears that neither the prehospital nor the hospital providers have the entire allergic reaction/anaphylaxis
picture. This effort also requires access to a potentially larger data set than obtainable through the Northwell
Health System resources. Previous research indicated that less than 50% of the prehospital cases met the
NIAID criteria for anaphylaxis and approximately 50% of patients are transported to Northwell facilities.
Assuming no differential effect, there will be only about 95 cases of prehospital anaphylaxis records available
through Northwell hospital EMRs. Similarly, from the Northwell hospital EMRs of patient transports to their
facility, an additional 50% of cases not identified with a prehospital provider impression might become
available adding an additional approximately 95 cases for the period starting January 1st, 2018 through
December 31st, 2019. It is unreasonable to assume that approximately 190 cases can provide enough data for
the development of an algorithm to model anaphylaxis in the prehospital setting from data entered into an
electronic medical record. Additional cases may be accessed through combining the data obtained from all
units in the New York City EMS 911 system and that from the New York State Statewide Planning and
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Research Cooperative System (SPARCS) data.29 That initiative will require substantial effort on both the
regional and state level that would not be possible within the time frame available for this dissertation.
However, an education initiative on behalf of the providers may prove useful in both the documentation
and diagnosis of anaphylaxis in the prehospital setting, while also indirectly aiding in the identification of these
patients to hospital-based providers. The Food Allergy Research and Education group (www.foodallergy.org)
created a Food Allergy and Anaphylaxis Emergency Action Plan (Figure 3.3). This easily readable and
actionable document allows for a layperson to connect the various system signs and symptoms into an
anaphylaxis diagnosis resulting in the administration of epinephrine. Although not completely consistent with
the NIAID/FAAN criteria for anaphylaxis diagnosis, it does capture many cases that would be identified
through those criteria. It is quite possible this document could be used by prehospital providers as an easy
algorithm for the identification of anaphylaxis and immediate treatment. However, it would have the limitation
of only being used when the provider suspected an allergic reaction or anaphylaxis event was already occurring,
resulting in the omission of cases resulting from first time anaphylaxis from unknown allergen triggers.
As an alternative, but following a similar process, we propose the use of an allergy assessment algorithm
to replace the simple questioning of whether the patient has an existing allergy within the already established
patient assessment methodology taught to prehospital providers (Figure 3.4). This algorithm has the benefit of
being like other algorithms familiar to providers, while also eliciting a connection of the various body systems
signs and symptoms to allergen exposure, and time of onset consistent with the NIAID/FAAN criteria.30-35
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Figure 3.3 Allergy & Anaphylaxis Emergency Care Plan-Food Allergy Research and Education
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Figure 3.4 Proposed Allergy Assessment Algorithm
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Limitations
This study carries with it the limitations of most retrospective cohort studies including
using data not specifically designed for the study and information bias. Although the data used
for this study was contained within the electronic medical records (EMRs) of the EMS agency, it
did not involve an in-depth review of all patient history narratives contained within those
records. However, since most EMS personnel are trained to document what they physically see
or are told by the patient, it is believed that most data elements are reliable for initial analysis.
The study also linked hospital-based records for a confirmation of prehospital diagnosis, which
also comes with significant inaccuracies. The various data sources were then linked together
through a common identification number in Microsoft Access, which was then exported for
review and analysis. The data queried from both prehospital and hospital based EMRs are also
subject to incompleteness by providers entering the data, as well as an inaccurate provider
impression/ICD diagnosis based upon patient history and presenting signs and symptoms.
Another limitation is that there was a low number of cases identified to reflect many of the
possible presentations of allergic reaction and anaphylaxis that would have served as a basis of
an algorithm-based model, similar to what might have been achieved through previous hospitalbased anaphylaxis identification.17 However, even with the limitations, we were able to be
guided for further intervention and research in this area.
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Conclusion
Anaphylaxis continues to be a diagnostic challenge in both the prehospital and hospital
setting. The diagnostic criteria promoted by the NIAID/FAAN is indeed accurate and can lead to
improved anaphylaxis identification and treatment with epinephrine. However, the apparent
“simplistic” appearance of the criteria belies a complex connection of patient history, signs and
symptoms, and allergen triggers that may not easily be visualized or conceptualized by
providers. The limited time for hospital-based providers to make the diagnosis before discharge
or admission, as well as the much more limited patient-provider interaction in the prehospital
setting, places pressure for the rapid identification of an allergic reaction and anaphylaxis.
Structural problems with in-hospital ICD coding of anaphylaxis and a lack of awareness of the
spectrum of the condition will continue unless modified by an education platform.
It is in education and awareness that the most potential benefit could be achieved, without
necessitating a predictive model to identify allergic reaction or anaphylaxis cases. The suggested
allergy assessment process provides an algorithmic approach to assessing each patient for an
allergy, and then connecting the various facets of the NIAID/FAAN criteria to suggest
anaphylaxis may exist earlier in the patient-provider interaction. With evidence suggesting
allergy prevalence is increasing, and with it the potential for increased episodes of anaphylaxis,
an initial required assessment of allergy for every patient might be a worthy goal.2, 36-38
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CHAPTER 5 – CONCLUSION
Overview
Anaphylaxis is considered a severe, potentially fatal, systemic allergic reaction that occurs
suddenly after contact with an allergy causing substance, which is estimated to affect up to 5% of
the population, resulting in fatal outcomes in 1% of hospitalizations and 0.1% of emergency
department patients.1-5 Diagnosis of anaphylaxis is difficult due to the complex nature of the
pathophysiological presentation, leading to delays in treatment that result in increased mortality.68

Medicine’s role is to help prevent and cure disease. Emergency medical services (EMS)
are an important link in this system and are frequently called upon to assist patients with severe
allergic reactions or anaphylaxis. It takes on added importance that providers recognize the
complex presentation of anaphylaxis, rapidly identify and manage the condition, and assist in
ascertaining the location of the population at risk for possible intervention. Early administration
of epinephrine may reduce hospitalizations and decrease the chance of mortality.9-12
Summary of Results
Collectively, the findings of this dissertation demonstrate that data obtained from the
prehospital environment can be used effectively for research that helps address issues noted in
the National EMS Research Agenda.

The findings also demonstrate that these data can be used

in a variety of methods to investigate a specific disease process, including population
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characteristics and location. Analysis of these data can be used to suggest opportunities to improve
care, data collection methods, and education initiatives. Our findings can be used as a benchmark
for future analyses, specifically for evaluating regional and state protocol changes effective
January 1, 2020.
Aim #1
In Aim #1, we characterized the population of patients with allergic reactions or
anaphylaxis in the prehospital environment. We were able to access and analyze 786 patient
records from patients treated by both Basic Life Support (BLS) and Advanced Life Support (ALS)
units of the Northwell Health System, operating within the New York City 911 System. Overall,
we were able to conclude that results from using only prehospital data was consistent with hospitalbased research findings, and the results can effectively “stand on their own”. The pediatric
population (<18 years) comprised 31% of the allergy and anaphylaxis cases, while the overall
pediatric patient population transported by the agency was 6.1%.
We were able to identify a structural deficiency in the prehospital electronic medical record
(EMR) that does not prompt or record an “allergen/trigger” for the allergic reaction or anaphylaxis
event. The incidence of allergic reaction in the population transported by this EMS agency was
0.60%, consistent with previous research reporting incidence of 0.5-1.0%. Male prevalence of
allergic reactions at an earlier, and female prevalence at a later age, was also observed with this
population. Forty-two percent of patients with signs and symptoms consistent with the regional
anaphylaxis protocol were given epinephrine.

Approximately 30% of patients meeting the

NIAID/FAAN criteria had epinephrine administered.
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Aim #2
In Aim #2, we conducted a spatial analysis of location point data obtained from the
EMRs of patients transported by the EMS in the Borough of Staten Island (Richmond County).
A cluster analysis was performed on census tract aggregated counts for patients with a history of
asthma, environmental allergies, or both. A total of 23,629 incidents resulted in 20,277 patient
transports, 2,039 patients refusing care and/or transport, and 1,146 patients being transported by
another agency ambulance. A total of 23,462 incident locations with patient present were used
for analysis.

Overall, there is a general association between asthma and environmental allergy

clusters, with elevated and reduced relative risk occurring in the same geographic areas. Specific
locations for patients with asthma histories were identified for potential intervention, including
two (2) NYCHA complexes. We were able to identify a unique area of low relative risk that
seems to contradict evidence of consistency of allergy sensitization across census tracts.
Aim #3
In Aim #3, we used prehospital data to investigate the creation and application of an
anaphylaxis algorithm to identify patients treated by EMS providers. A total of 222,681 records
are available to be analyzed for this study. Only cases transported to Northwell Health System
facilities, where patients were 18 years or older were further considered for additional inquiry
(n=111,127, 49.9%). Using a screen based upon NIAID/FAAN anaphylaxis diagnostic criteria,
and additional 4 cases were identified over an 8-month retrospective review. Using a
retrospective hospital records review of all transports for the EMS agency over a one-month
period, an additional ten (10) cases of allergy or anaphylaxis were identified where the provider
impression was not “Allergic Reaction”. Inaccuracy in both hospital and prehospital
environments make consistent identification of anaphylaxis patients difficult, and development
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of an algorithm or model for application premature. Improved provider education, and a change
of approach to allergy history assessment, may be a better approach.
Policy Implications and Future Research Opportunities
The reliance on hospital-based research and data, while very important to improving
population health, obscures benefit of using data from other sources, including that of prehospital
agencies. While individual hospitals can provide insight as to the types and conditions of
patients brought into the facility, they lack the global view of an entire geographic region that an
analysis of emergency response data can provide. While this option may only be immediately
available to agencies as large as the Northwell Health System, congregated data from the
National EMS Information System can be accessed to obtain this “global” view of an area.
Aim #1
There were several findings in this study that have significant policy implications. First,
is the general lack of an area in the EMR or patient care record to effectively evaluate a patients
allergy history, including allergen trigger identification. Serious consideration should be given
to either improving the framework of the record to coincide with an assessment of an allergy
history to include, type of allergy, potential allergen triggers, patient physiological allergic
reaction response, history of anaphylaxis, and possession/prescription of an epinephrine
autoinjector (EAI).
The relatively low rates of epinephrine administration for anaphylaxis in both the hospital
and prehospital settings has, is, and continues to be a concern. In our study, less than 50% of the
patients meeting the regional protocol for anaphylaxis, and approximately 30% meeting the
NIAID/FAAN criteria, were administered epinephrine. There has been some support for
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revisiting the NIAID/FAAN criteria for diagnosis, but the treatment with epinephrine is still the
standard.13 The unpredictable nature of the progression from allergic reaction to anaphylaxis
resulting in a fatal outcome places a significant number of encountered patients at risk.
Increasing allergy prevalence may lead to increased patient encounters with anaphylaxis, which
in turn increases the risk of death if treatment with epinephrine is absent or delayed. Although
relatively rare, reduction in the risk of death and alleviation of adverse signs and symptoms must
be a priority.
Our study identified some unique issues involving age and epinephrine administration in
the prehospital setting that needs to be further investigated. The use of epinephrine was less
likely in the newborn to 9 years of age group as compared to the age 20 to 29 years of age group,
and age group 11 to 17 was more likely to receive epinephrine as compared to those 18 years and
older. The under-use of epinephrine in the infant to 9 years of age may be potentially explained
by the high probability that an epinephrine auto-injector (EAI) is carried and administered by a
caregiver, while it is more likely that an EAI is not carried by a person in the 10-19 year of age
group, in conjunction with other factors such as risk-taking behavior, not carrying or fear of
using the device, not thinking it is necessary, or having an expired device.14-19 Hesitancy in
treating younger pediatric patients, as well as potential errors in identification of anaphylaxis by
paramedics for this age group, may also influence the administration of epinephrine.20-22 There
is some evidence that epinephrine administration rates are improved through relatively easy
education platforms.23, 24 It is here that EMS providers can participate in both research and
intervention by evaluating patients allergy status to determine EAI compliance and accessibility,
and providing patient “refresher” education on the need for epinephrine. This in turn should also
heighten the providers awareness of anaphylaxis and comfort with administering epinephrine.
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Aim #2
In Aim #2, we also had several findings that have significant policy implications and
opportunities for additional research, most notably the conflating of adverse drug reactions with
medication allergy.

We were alerted to this issue when an initial data review indicated that

69% of the patients encountered had a documented medication allergy, when according to the
World Allergy Organization suggest that is be closer to 1 in 100 in the general population.25
This situation is formidably grounded by the health care providers failing to maintain the
patient’s medication records to discriminate between types of adverse drug reactions (ADRs), or
educating the patient on the drug reaction, leading to a propagation of unreliable information.26
This could have profoundly dangerous consequences for the patient.27
The American Academy of Allergy, Asthma, and Immunology estimates that true drug
hypersensitivity reactions only account for 5-10% of those categorized as adverse drug
reactions.28, 29 It is unlikely that prehospital providers conduct in-depth questioning of a patient
as to what happens when they take a medication to properly discriminate out a true allergy. It is
also unlikely the provider would have altered the entry of medication allergy, as the EMR does
not reflect the nuances of an adverse drug reaction to answer succinctly. Recommendations for
improving the patient questioning and documentation of medication adverse reactions can still be
promoted to reduce the possibility of poor health outcomes. Also, this issue may benefit from a
prospective intervention analysis, and a potential restructuring of the data entry model of the
EMR.
This study identified potential areas of intervention where patients with an asthma history
are located, which included two of the ten NYCHA complexes located in Richmond County.
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Neighborhood environmental factors that have been linked to asthma include, but are not limited
to, outdoor air pollutants, poor housing quality, and disproportionate pollution burdens found in
low-income, minority neighborhoods.30-34 There are also physical and social characteristics that
may impact individual health including poverty, residential segregation, inadequate
transportation, unsafe recreation spaces, and social networks.35 It has been suggested that the
higher prevalence of asthma in some inner-cities can be better explained by demographic factors,
and not simply by living in an urban environment.36
The two identified NYCHA locations have rates of asthma that are substantially different
then the census tract in which they are contained and are within the identified clusters of higher
relative risk. It is not implied or stated that the patients transported by the EMS agency were
suffering from asthma at the time of transport; however, it can be inferred that a substantially
sick population being transported by ambulance might be representative of an overall population
that might be adversely impacted by asthma and interventions undertaken to investigate and
improve the overall health of that population.
Finally, we were able to identify a unique area of low relative risk that seems to
contradict evidence of consistency of allergy sensitization across census tracts. Further
investigation may prove enlightening to the increasing prevalence of allergic diseases. It has
been suggested the overall prevalence of allergic sensitization does not vary across US census
regions, except in early life; and allergen-specific sensitization differs based on
sociodemographic and regional factors.37 The attributes of the census tracts identified in this
cluster need to be further evaluated to determine what contributes to the lower relative risk. In
addition, an analysis of prior and subsequent years of data, or access to a complete incident data
set for the county, may prove enlightening to what may contribute to development of allergies.
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Aim #3
Considering deficiencies in the ability of providers in either the prehospital or hospital
arenas to accurately identify and chart the diagnosis of anaphylaxis, the approach to identify
allergic reactions and anaphylaxis through a modelling of prehospital data may be premature.
Based upon the limited results obtained from our initial attempts, a bi-directional data gathering
effort needs to be undertaken to get enough information to determine frequency and combinations
of various signs and symptoms of each body system involved in the cases of anaphylaxis. The
data must be bi-directional since it appears that neither the prehospital nor the hospital providers
have the entire allergic reaction/anaphylaxis picture. This might be obtainable by linking the
region’s prehospital data with the New York State Statewide Planning and Research Cooperative
System (SPARCS) data.38 This suggestion is not without significant bureaucratic hurdles, but
could potentially provide the analysis necessary for this type of modeling.
However, the advancement of knowledge through interventions with prehospital providers
in both identification and documentation may serve as the initial starting point of such a goal. The
proposed use of an allergy assessment algorithm, within the already established patient assessment
methodology taught to prehospital providers, may prove effective while also instituting
consistency with obtaining allergy data. This algorithm has the benefit of being like algorithms
already familiar to providers, while also eliciting a connection of the various body systems signs
and symptoms to allergen exposure, and time of onset consistent with the NIAID/FAAN criteria.3944
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Key Strengths
This dissertation is unique in several ways. Firstly, we use available prehospital data to
evaluate a disease process not typically considered important to EMS research. Past research tends
to focus on outcomes of out-of-hospital cardiac arrest, stroke, myocardial infarction, and other
conditions deemed “emergent”, with little consideration to anaphylaxis. This dissertation has
characterized a population of patients more in-depth than previous studies involving prehospital
anaphylaxis, including age, gender, race/ethnicity, as well as temporality. It also provided an
initial differential evaluation of allergic reaction/anaphylaxis management based upon level of
EMS provider. We were able to also identify structural barriers in data gathering that could
potentially impact patient care and management, including lack of an entry point to differentiate
anaphylaxis from allergic reaction, allergen trigger identification, and differentiation of medication
allergies from adverse drug reactions.
The use of GISc with individual EMS incident point data is also unique, especially when
applied to a specific disease or condition. Although this dissertation used asthma and allergy
history as a focus, similar applications can be performed for other conditions like heart disease,
diabetes, psychiatric disorders, cancer, and chronic renal failure. The use of this agency’s data
allowed for a broad overview of the population that would not be found through an individual
hospital location perspective.
Limitations
From an overall and general perspective, the main limitations are utilizing data not
specifically identified for the disease under investigation, lack of confirmed quality and reliability
of the data, information and selection bias, and generalizability of our findings.
Aim #1 Limitations
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Although the data used for this study was contained within the electronic medical records
(EMRs) of the EMS agency, it had to be gathered from both a query of the records and abstraction
of the narratives that were not able to be queried through normal electronic means. The various
data sources were then linked together through a common identification number. The data queried
from the EMR are also subject to incompleteness by providers entering the data, as well as an
inaccurate provider impression based upon patient history and presenting signs and symptoms.
Since most EMS personnel are trained to document what they physically see or are told by the
patient, it is believed that most data elements are reliable for analysis.
Aim #2 Limitations
The accuracy of the recorded data might be compromised as patients may be poor
historians and not report all their allergies, and providers may not be diligent about obtaining an
allergy or asthma history or failing to document relevant findings. Additional limitations include
potential geocoding errors leading to incorrect incident locations, and the use of census tracts as
the unit of aggregation, which can have considerable variation in terms of size and population.
However, the use of census tracts was deemed reasonable since further research could utilize
available tract level demographic, housing, social and economic profiles. Census tracts also
represent a defined unit for targeting government resources and interventions.
Aim #3 Limitations
Although the data used for this study was contained within the electronic medical records
(EMRs) of the EMS agency, it did not involve an in-depth review of all patient history narratives
contained within those records. However, as with Aim #1, since most EMS personnel are trained
to document what they physically see or are told by the patient, it is believed that most data
elements not involving a narrative are reliable for initial analysis. The study also linked hospital129

based records for a confirmation of prehospital diagnosis, which also comes with significant
inaccuracies. Various data sources were then linked together through a common identification
number and then exported for review and analysis. The data queried from both prehospital and
hospital based EMRs are subject to incompleteness by providers entering the data, as well as an
inaccurate provider impression/ICD diagnosis based upon patient history and presenting signs
and symptoms. Another limitation is that there was a low number of cases identified to reflect
many of the possible presentations of allergic reaction and anaphylaxis that would have served as
a basis of an algorithm-based model, similar to what might have been achieved through previous
hospital-based anaphylaxis identification.45 However, even with the limitations, we were able to
be guided for further intervention and research in this area.
Overall Conclusions and Future Directions
While we recognize the relatively low rate of anaphylaxis mortality and the rarity of the
event, the evidence indicating increasing prevalence of allergies in the population should give
pause. In the overall number of allergic reaction cases, there is a significant percentage
involving pediatric patients that is higher with respect to the overall volume encountered by the
EMS agency. It is reasonable to generalize the results of this dissertation to estimate that
Approximately, 11,000 people in New York City annually may potentially suffer severe allergic
reaction or anaphylaxis. In an urban location with a population of over 8 million, up to 10% of
people suffer from some type of medication reaction, 8% have food allergies, and a rising
prevalence of allergic diseases over the last 50 years.25
As was mentioned earlier in this dissertation, this initial analysis was intended to
benchmark anaphylaxis for future analysis after a state and regional protocol change. On
January 1st, 2020, statewide implementation of the collaborative protocols occurred. New York
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City, which operates slightly differently from the rest of the state, implemented their unified
protocols on January 1st, 2021. With the rise of SARS-CoV-2 in 2020, and the subsequent
alteration to response patterns and demand, we anticipate a prolonged period before returning to
a steady state where allergy and anaphylaxis can once again be evaluated. We look forward to
that investigation.

131

Chapter #5-Citations
1.
2.

3.

4.
5.
6.
7.

8.
9.

10.

11.
12.
13.
14.

15.
16.

17.
18.

Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World
Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal. 2015;8:32.
Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis:
mortality rate and risk factors. The Journal of Allergy and Clinical Immunology: In Practice.
2017;5(5):1169-1178.
Wood RA, Camargo Jr CA, Lieberman P, et al. Anaphylaxis in America: the prevalence and
characteristics of anaphylaxis in the United States. Journal of Allergy and Clinical Immunology.
2014;133(2):461-467.
Caroline NL, Elling B, Smith M. Nancy Caroline's emergency care in the streets. Vol 1: Jones &
Bartlett Publishers; 2012.
Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis
in the United States. Journal of allergy and clinical immunology. 2014;133(4):1075-1083.
Castells M. Diagnosis and management of anaphylaxis in precision medicine. Journal of Allergy
and Clinical Immunology. 2017;140(2):321-333.
Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in
Ontario: a retrospective review of cases from 1986 to 2011. Allergy, Asthma & Clinical
Immunology. 2014;10(1):1-8.
Anchor J, Settipane RA. Appropriate use of epinephrine in anaphylaxis. The American journal of
emergency medicine. 2004;22(6):488-490.
Fleming JT, Clark S, Camargo Jr CA, Rudders SA. Early treatment of food-induced anaphylaxis
with epinephrine is associated with a lower risk of hospitalization. The Journal of Allergy and
Clinical Immunology: In Practice. 2015;3(1):57-62.
Gabrielli S, Clarke A, Morris J, et al. Evaluation of prehospital management in a Canadian
emergency department anaphylaxis cohort. The Journal of Allergy and Clinical Immunology: In
Practice. 2019;7(7):2232-2238. e2233.
Andrew E, Nehme Z, Bernard S, Smith K. Pediatric anaphylaxis in the prehospital setting:
incidence, characteristics, and management. Prehospital Emergency Care. 2018;22(4):445-451.
Dorris S. Fatal food anaphylaxis: Registering a rare outcome. Annals of Allergy, Asthma &
Immunology. 2020;124(5):445-446.
Turner PJ, Worm M, Ansotegui IJ, et al. Time to revisit the definition and clinical criteria for
anaphylaxis? World Allergy Organization Journal. 2019;12(10).
Gallagher M, Worth A, Cunningham‐Burley S, Sheikh A. Epinephrine auto‐injector use in
adolescents at risk of anaphylaxis: a qualitative study in Scotland, UK. Clinical & Experimental
Allergy. 2011;41(6):869-877.
Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis:
missed opportunities. Journal of asthma and allergy. 2018;11:143.
Warren CM, Zaslavsky JM, Kan K, Spergel JM, Gupta RS. Epinephrine auto-injector carriage
and use practices among US children, adolescents, and adults. Annals of Allergy, Asthma &
Immunology. 2018;121(4):479-491.
Monks H, Gowland M, MacKenzie H, et al. How do teenagers manage their food allergies?
Clinical & Experimental Allergy. 2010;40(10):1533-1540.
Macadam C, Barnett J, Roberts G, et al. What factors affect the carriage of epinephrine autoinjectors by teenagers? Clinical and translational allergy. 2012;2(1):1-7.
132

19.
20.
21.

22.
23.
24.

25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.

37.

38.
39.

Noimark L, Wales J, Du Toit G, et al. The use of adrenaline autoinjectors by children and
teenagers. Clinical & Experimental Allergy. 2012;42(2):284-292.
Lammers R, Willoughby-Byrwa M, Fales W. Medication errors in prehospital management of
simulated pediatric anaphylaxis. Prehospital Emergency Care. 2014;18(2):295-304.
Guise J-M, Hansen M, O'Brien K, et al. Emergency medical services responders’ perceptions of
the effect of stress and anxiety on patient safety in the out-of-hospital emergency care of children:
a qualitative study. BMJ open. 2017;7(2).
Jeruzal JN, Boland LL, Frazer MS, et al. Emergency medical services provider perspectives on
pediatric calls: A qualitative study. Prehospital Emergency Care. 2019.
Posner LS, Camargo Jr CA. Update on the usage and safety of epinephrine auto-injectors, 2017.
Drug, healthcare and patient safety. 2017;9:9.
El Turki A, Smith H, Llewellyn C, Jones CJ. A systematic review of patients', parents' and
healthcare professionals' adrenaline auto-injector administration techniques. Emergency Medicine
Journal. 2017;34(6):403-416.
Pawankar R, Canonica GW, Holgate ST, Lockey RF. White book on allergy 2011–2012
executive summary. World Allergy Organization. 2011.
Stephens M, Fox B, Kukulka G, Bellamy J. Medication, allergy, and adverse drug event
discrepancies in ambulatory care. FAMILY MEDICINE-KANSAS CITY-. 2008;40(2):107.
Horsham P. Allergy or adverse effect: Teach patients the difference.
Warrington R, Silviu-Dan F. Drug allergy. Allergy, Asthma & Clinical Immunology. 2011;7(1):18.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. American family
physician. 2003;68(9):1781-1790.
Corburn J, Osleeb J, Porter M. Urban asthma and the neighbourhood environment in New York
City. Health & place. 2006;12(2):167-179.
Krieger J, Higgins DL. Housing and health: time again for public health action. American journal
of public health. 2002;92(5):758-768.
Mott L. The disproportionate impact of environmental health threats on children of color.
Environmental health perspectives. 1995;103(suppl 6):33-35.
Milligan KL, Matsui E, Sharma H. Asthma in urban children: epidemiology, environmental risk
factors, and the public health domain. Current allergy and asthma reports. 2016;16(4):33.
Bryant-Stephens T. Asthma disparities in urban environments. Journal of Allergy and Clinical
Immunology. 2009;123(6):1199-1206.
Kawachi I, Berkman LF. Neighborhoods and health: Oxford University Press; 2003.
Keet CA, McCormack MC, Pollack CE, Peng RD, McGowan E, Matsui EC. Neighborhood
poverty, urban residence, race/ethnicity, and asthma: rethinking the inner-city asthma epidemic.
Journal of Allergy and Clinical Immunology. 2015;135(3):655-662.
Salo PM, Arbes Jr SJ, Jaramillo R, et al. Prevalence of allergic sensitization in the United States:
results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006.
Journal of Allergy and Clinical Immunology. 2014;134(2):350-359.
Data I. Statewide Planning and Research Cooperative System (SPARCS) Data Governance
Policy and Procedure Manual.
Duff JP, Topjian AA, Berg MD, et al. 2019 American Heart Association focused update on
pediatric advanced life support: an update to the American Heart Association guidelines for
cardiopulmonary resuscitation and emergency cardiovascular care. Circulation.
2019;140(24):e904-e914.
133

40.

41.
42.

43.
44.

45.

Panchal AR, Berg KM, Hirsch KG, et al. 2019 American Heart Association focused update on
advanced cardiovascular life support: use of advanced airways, vasopressors, and extracorporeal
cardiopulmonary resuscitation during cardiac arrest: an update to the American Heart Association
guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation.
2019;140(24):e881-e894.
Bosson N, Kaji AH, Gausche-Hill M, et al. Evaluation of trauma triage criteria performance in a
regional trauma system. Prehospital emergency care. 2019.
Hoffman JR, Mower WR, Wolfson AB, Todd KH, Zucker MI. Validity of a set of clinical criteria
to rule out injury to the cervical spine in patients with blunt trauma. New England Journal of
Medicine. 2000;343(2):94-99.
Kasner SE. Clinical interpretation and use of stroke scales. The Lancet Neurology. 2006;5(7):603612.
Kontos MC, Gunderson MR, Zegre‐Hemsey JK, et al. Prehospital Activation of Hospital
Resources (PreAct) ST‐Segment–Elevation Myocardial Infarction (STEMI): A Standardized
Approach to Prehospital Activation and Direct to the Catheterization Laboratory for STEMI
Recommendations From the American Heart Association's Mission: Lifeline Program. Journal of
the American Heart Association. 2020;9(2):e011963.
Harduar-Morano L, Simon MR, Watkins S, Blackmore C. Algorithm for the diagnosis of
anaphylaxis and its validation using population-based data on emergency department visits for
anaphylaxis in Florida. Journal of allergy and clinical immunology. 2010;126(1):98-104. e104.

134

APPENDIX A-Variables Used in Analysis
Table 1.2-Variables Used in Analysis.
Variables
Area of Interest
Demographics

Temporal

Trigger

Signs & Symptoms

Category

Sub-Category

Variable/Combination
/Measurement

Age
Gender
Race/Ethnicity
Day
Month
Year
Food
Medicine
Environmental
Other
Unknown
Missing
Mucosocutaneous

Airway

Skin

Respiratory

Effort
Rate
Quality
Measurements

Cardiovascular

Gastrointestinal

Lightheaded/Dizzy
Syncope
Chest
Pain/Discomfort
Hypotension
Tachycardia
Nausea
Vomiting
Abdominal
Pain/Discomfort
Diarrhea

Partial/Fully
Obstructed/Drooling/Stridor
Difficulty Swallowing/Voice
Change
Hives
Flushed
Swollen
Pruritis/Erythema/Swollen
Labored/Shallow Breathing
Dyspnea/Shortness of Breath
Slow/Rapid Breathing
Diminished/Wheezing
Pulse Oximetry
Respiratory Rate

Age-Adjusted
Age-Adjusted

NIAID/FAAN Criteria
NYC Adult/Pediatric Protocol
*-Denotes categorical variables created to coincide with accepted criteria.
**-Denotes some variables that were combined to due to lack of frequency in the data set to be meaningful.
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APPENDIX B-NYC Pediatric BLS Protocol

Figure 1.3-NYC BLS Pediatric Anaphylaxis Protocol
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APPENDIX C-NYC Adult BLS Protocol

Figure 1.4-NYC BLS Adult Anaphylaxis Protocol

137

APPENDIX D-Trigger Frequency by Age Decade
Figure 1.5-Trigger Frequency by Age Decade

Top left: Decades 0-29; Top right: Decades 30-59; Bottom: Decades 60-89.
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APPENDIX E-Frequency of Patient Signs and
Symptoms and Epinephrine Administration
Table 1.27-Frequency of Patient Signs and Symptoms presenting and administration of
epinephrine by EMS providers.*
Patient
Characteristic

Overall
n (%)

EMS Epi
n (%)

𝜒2

pvalue

Odds Ratio
(95% CI)

pvalue

EMS Epi Given
Mucosocutaneous
S & Sx

2.925
(2.0594.154)

253 (32)

87 (34)

37.5979

<.0001

21 (3)

14 (67)

27.5443

<.0001

27 (3)

10 (37)

4.9754

0.0257

Hives

135 (17)

55 (41)

36.3776

<.0001

Flushed

107 (14)

44 (41)

28.7413

<.0001

Swollen

37 (5)

17 (46)

13.9498

0.0002

Pruritis/Erythema/
Rash

111 (14)

34 (31)

6.5901

0.0103

1.783
(1.1422.784)

0.0110

1.676
(0.9512.956)

0.0742

Respiratory S & Sx

307 (39)

110 (36)

62.6475

<.0001

4.053
(2.8275.811)

<.0001

7.515
(4.50012.550)

<.0001

Dyspnea/SOB

247 (31)

104 (43)

99.4505

<.0001

Labored/Shallow
Breathing

64 (8)

36 (56)

50.4272

<.0001

67 (9)

40 (60)

64.0229

<.0001

Airway
Partially or Fully
Obstructed/
Drooling/Stridor
Difficulty
Swallowing/
Voice Change
Skin

8.250
(3.27020.813)
2.426
(1.0885.411)
3.273
(2.1974.877)
3.126
(2.0304.813)
3.366
(1.7216.583)

<.0001

Odds
pRatio
value
(95% CI)
EMS Epi Given not
PTA
3.622
(2.269<.0001
5.756)

<.0001

0.0303

<.0001

<.0001

0.0004

12.665
(4.61434.765)
1.462
(0.4075.250)
3.393
(2.0665.574)
4.690
(2.7927.876)
3.306
(1.4737.420)

<.0001

0.5608

<.0001

<.0001

0.0037

Effort
5.784
(4.1048.335)
5.746
(3.3879.750)

<.0001

<.0001

10.075
(6.06816.727)
13.076
(7.02224.347)

<.0001

<.0001

Rate
Slow or Rapid
Breathing

6.838
(4.04811.550)

<.0001

16.827
(8.93231.700)

<.0001

Lung Sounds
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Diminished/Wheeze
Lung Sounds

69 (9)

36 (52)

42.697

<.0001

SPO2 <= 92

56 (7)

25 (45)

Respiratory rate
> 24***

23 (3)

14 (61)

Cardiovascular S
& Sx

256 (33)

74 (29)

11.9072

0.0006

Lightheaded/
Dizziness

42 (5)

5 (12)

2.3674

0.1239

Syncope

17 (2)

2 (12)

0.9547

0.3285

Chest Pain/
Discomfort

26 (3)

6 (23)

0.0464

0.8295

Hypotension
(Age Adjusted)

31 (4)

10 (32)

1.936

0.1646

Tachycardia
(Age Adjusted)

240 (31)

77 (32)

22.6951

<.0001

4.835
(2.9078.041)

<.0001

11.272
(6.12720.741)

<.0001

Metrics
3.312
(1.8965.784)
6.148
(2.61314.467)

1.843
(1.2992.614)
0.482
(0.1861.245)
0.484
(0.1102.139)
1.107
(0.4382.803)
1.715
(0.7963.695)
2.323
(1.6343.303)

<.0001

<.0001

0.0006

0.1318

0.3388

0.8295

0.1687

<.0001

7.287
(3.80513.955)
7.597
(2.91119.828)

2.483
(1.5743.916)
0.672
(0.2321.948)
0.998
(0.2174.580)
1.163
(0.3863.502)
3.306
(1.4737.420)
3.562
(2.2435.656)

<.0001

<.0001

<.0001

0.4643

0.9979

0.7886

0.0037

<.0001

1.257
1.369
(0.7940.3298
(0.7410.3167
1.989)
2.529)
1.072
1.727
Nausea
40 (5)
9 (23)
0.0318
0.8585
(0.5000.8585
(0.7180.2223
2.298)
4.154)
1.607
1.771
Vomiting
75 (10)
22 (29)
3.1254
0.0771
(0.9470.0789
(0.8660.1176
2.729)
3.626)
0.831
0.968
Abdominal
27 (3)
5 (19)
0.1357
0.7126
(0.3100.7130
(0.2780.9591
Pain/Discomfort
2.228)
3.373)
0.405
0.782
Diarrhea
10 (1)
1 (10)
0.7797
0.3772
(0.0510.3931
(0.0950.8189
3.221)
6.431)
*Significant associations are highlighted. OR are presented for all cases where EMS administered epinephrine and
for those cases where it was not given prior to arrival (PTA). Signs and symptoms are combined where listed, and
no reference categories were used for analysis.
Gastrointestinal
S & Sx

117 (15)

29 (25)

0.9524

0.3291
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APPENDIX F-SAS Syntax
SAS Coding
SAS Coding of Data
libname allergy 'C:\Users\sphuser\Documents\Anaphylaxis\Working Files';
run;
********import data here********;
PROC IMPORT OUT= WORK.Allergy
DATAFILE= "C:\Users\sphuser\Documents\Anaphylaxis\Working Fi
les\Working Data Set-Safe2.xlsx.xls"
DBMS=EXCEL REPLACE;
RANGE="Complete_Data_Set";
GETNAMES=YES;
MIXED=NO;
SCANTEXT=YES;
USEDATE=YES;
SCANTIME=YES;
RUN;
Data Test;
set allergy;
where division_num < 5;
if AGE_MODIFIER = 'Months'
then age_year_conv = AGE/12;
else if AGE_MODIFIER = 'Days'
then age_year_conv = AGE/365.25;
else if AGE_MODIFIER = 'Years'
then age_year_conv = AGE;
If age_year_conv >= 18
then age_class = 1;
else if 0 < age_year_conv < 18
then age_class = 0;
If gender = 'Male'
then gender_class = 1;
else if gender = 'Female'
then gender_class = 0;
if _trigger < 7
then trigger = _trigger;
else trigger = 2;
If 0
then
else
then
else
then
else
then
else
then
else

< age_year_conv < 10
age_class_new = 0;
if 10 <= age_year_conv
age_class_new = 1;
if 20 <= age_year_conv
age_class_new = 2;
if 30 <= age_year_conv
age_class_new = 3;
if 40 <= age_year_conv
age_class_new = 4;
if 50 <= age_year_conv

< 20
< 30
< 40
< 50
< 60
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then
else
then
else
then
else
then

age_class_new = 5;
if 60 <= age_year_conv < 70
age_class_new = 6;
if 70 <= age_year_conv < 80
age_class_new = 7;
if 80 <= age_year_conv
age_class_new = 8;

If 0
then
else
then
else
then
else
then
else
then
else
then
else
then

< age_year_conv < 10
cems_age = 0;
if 10 <= age_year_conv
cems_age = 1;
if 19 <= age_year_conv
cems_age = 2;
if 25 <= age_year_conv
cems_age = 3;
if 36 <= age_year_conv
cems_age = 4;
if 51 <= age_year_conv
cems_age = 5;
if 65 <= age_year_conv
cems_age = 6;

<= 18
<= 24
<= 35
<= 50
<= 64

If 0 < age_year_conv < 10
then decade0 = 1;
else decade0 =0;
if 10 <= age_year_conv < 20
then decade1 = 1;
else decade1 =0;
if 20 <= age_year_conv < 30
then decade2 = 1;
else decade2 =0;
if 30 <= age_year_conv < 40
then decade3 = 1;
else decade3 =0;
if 40 <= age_year_conv < 50
then decade4 = 1;
else decade4 =0;
if 50 <= age_year_conv < 60
then decade5 = 1;
else decade5 =0;
if 60 <= age_year_conv < 70
then decade6 = 1;
else decade6 =0;
if 70 <= age_year_conv < 80
then decade7 = 1;
else decade7 =0;
if 80 <= age_year_conv
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then decade8 = 1;
else decade8 =0;
*ethnicity/race;
If RACE_ASIAN = 1 and RACE_HISPANIC NE 1
then asian = 1;
else asian = 0;
If RACE_BLACK = 1
then black = 1;
else black = 0;
If RACE_HISPANIC = 1 and RACE_BLACK NE 1
then hispanic = 1;
else hispanic = 0;
If RACE_NATIVE_AMERICAN = 1 and RACE_HISPANIC NE 1
then native_american = 1;
else native_american = 0;
If RACE_PACIFIC_ISLANDER = 1 and RACE_HISPANIC NE 1
then pacific_islander = 1;
else pacific_islander = 0;
If RACE_WHITE = 1 and RACE_HISPANIC NE 1 and RACE_ASIAN NE 1
then white = 1;
else white = 0;
If RACE_UNKNOWN = 1
then unknown = 1;
else unknown = 0;
If RACE_ASIAN NE 1 and
RACE_BLACK NE 1 and
RACE_HISPANIC NE 1 and
NATIVE_AMERICAN NE 1 and
RACE_PACIFIC_ISLANDER NE 1 and
RACE_WHITE NE 1 and
RACE_UNKNOWN NE 1
then race_not_specified = 1;
else race_not_specified = 0;
If white = 1
then race_category = 0;
else if black =1
then race_category = 1;
else if asian = 1
then race_category = 2;
else if hispanic = 1
then race_category = 3;
else if pacific_islander = 1
then race_category = 4;
else if unknown = 1
then race_category = 5;
else if race_not_specified = 1
then race_category = 6;
*Age
If 0
then
else
then
else

classes by NIAID/FAAN Criteria;
< age_year_conv <= 1
age_class_old = 0;
if 1 < age_year_conv <= 10
age_class_old = 1;
if 10 < age_year_conv < 18
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then age_class_old = 2;
else if 18 <= age_year_conv
then age_class_old = 3;
*Hypotension Criteria;
If age_class_old = 0
then hypotension=70;
If age_class_old = 1
then hypotension=(round(70+(2*age_year_conv)));
if age_class_old = 2
then hypotension=90;
if age_class_old = 3
then hypotension=90;
If 0 < Systolic_1 < hypotension
then pthypotensive=1;
else pthypotensive=0;
*Tachycardia Criteria;
If (pulse_1 > 170 and age_year_conv <= 1) or
(pulse_1 > 130 and 1 < age_year_conv < 11) or
(pulse_1 > 120 and 10 < age_year_conv < 18) or
(pulse_1 > 100 and age_year_conv >= 18)
then pttachy = 1;
else pttachy = 0;
*allergy history;
if nsaids = 1 or
ace_inhibitor = 1 or
_antibiotic = 1 or
contrast_dye = 1 or
other_rx = 1
then med_allergy_present = 1;
else med_allergy_present = 0;
if food_allergy = 1 or
environmental_allergy = 1 or
_envenomation = 1 or
_other = 1 or
_unknown = 1
then env_allergy_present = 1;
else env_allergy_present = 0;
If env_allergy_present = 0 and med_allergy_present = 0
then allergyhx1= 0;
else if env_allergy_present = 1 and med_allergy_present = 0
then allergyhx1 = 1;
else if env_allergy_present = 0 and med_allergy_present = 1
then allergyhx1 = 2;
else if env_allergy_present = 1 and med_allergy_present = 1
then allergyhx1 = 3;
*Trigger setting;
if _trigger = 1 then
food_trigger = 1;
else food_trigger =0;
if _trigger = 2 then
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med_trigger = 1;
else med_trigger =0;
if _trigger = 3 then
venom_trigger = 1;
else venom_trigger =0;
if _trigger = 4 then
env_trigger = 1;
else env_trigger =0;
if _trigger = 5 then
other_trigger = 1;
else other_trigger =0;
if _trigger = 6 then
unk_trigger = 1;
else unk_trigger =0;
If _trigger = 1
then new_trigger
else if _trigger
then new_trigger
else if _trigger
then new_trigger
else if _trigger
then new_trigger
else if _trigger
then new_trigger
else if _trigger
then new_trigger

=
=
=
=
=
=
=
=
=
=
=

1;
2
2;
3
3;
4
4;
5 or _trigger = 7
5;
6
6;

If new_trigger = 1 or new_trigger = 3 or new_trigger = 4 or new_trigger = 5
then hxtrigger = 1;
else if new_trigger = 2 then hxtrigger = 2;
else if new_trigger = 6 then hxtrigger = 0;
*backup
*Data test;
*set test;
*If _trigger = 1
then new_trigger_1= 1;
*else if _trigger = 2
then new_trigger_1 = 2;
*else if _trigger = 3 or _trigger = 4
then new_trigger_1 = 3;
*else if _trigger = 5 or _trigger = 7
then new_trigger_1 = 4;
*else if _trigger = 6
then new_trigger_1 = 5;
*run;
*mucosocutaneous symptoms;
If AIRWAY_PARTIALLY_OBSTRUCTED = 1 or
AIRWAY_FULLY_OBSTRUCTED = 1 or
AIRWAY_DIFFICULTY_SWALLOWING = 1 or
AIRWAY_DROOLING = 1 or
AIRWAY_STRIDOR or
SKIN_COND_DIAPHORETIC or
SKIN_COND_MOIST or
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SKIN_COND_ERYTHEMA = 1 or
SKIN_COND_HIVES = 1 or
SKIN_COND_ITCHY = 1 or _pruritis = 1 or
SKIN_COND_SWOLLEN = 1 or swelling_face_lips = 1 or swelling_tongue_tingling =
1 or
SKIN_COND_RASH = 1 or
SKIN_COLOR_FLUSHED = 1 or
SKIN_COLOR_PALE
then mucosocutaneous_rep = 1;
else mucosocutaneous_rep = 0;
If AIRWAY_PARTIALLY_OBSTRUCTED = 1 or
AIRWAY_FULLY_OBSTRUCTED =1 or
AIRWAY_DROOLING = 1 or
AIRWAY_STRIDOR = 1
then MSSXA = 1;
else if AIRWAY_DIFFICULTY_SWALLOWING = 1 or
voice_change = 1
then MSSXA = 2;
else MSSXA = 0;
If SKIN_COND_ITCHY = 1 or
SKIN_COND_ERYTHEMA = 1 or
SKIN_COND_RASH = 1
then MSSXS = 1;
else MSSXS = 0;
If MSSXS > 0 or MSSXA > 0 or SKIN_COND_HIVES = 1 or SKIN_COND_SWOLLEN = 1 or
SKIN_COLOR_FLUSHED = 1
then MUCOSOCUTANEOUS = 1;
else MUCOSOCUTANEOUS = 0;
*respiratory symptoms
Loss of 20% or more of respiratory cases by not including dyspnea_sob from
narrative review
No loss of cases with removing Resp_1 > 24;
If dyspnea_sob = 1 or
AIRWAY_STRIDOR = 1 or
BREATHING_QUALITY_LABORED = 1 or
BREATHING_QUALITY_SHALLOW = 1 or
LUNG_SOUNDS_L_DIMINISHED = 1 or
LUNG_SOUNDS_R_DIMINISHED = 1 or
LUNG_SOUNDS_L_WHEEZE = 1 or
LUNG_SOUNDS_R_WHEEZE =1 or
BREATHING_RATE_SLOW = 1 or
BREATHING_RATE_RAPID =1 or
SPO2 <= 92 or
voice_change = 1
then respiratory_rep = 1;
else respiratory_rep = 0;
if BREATHING_QUALITY_LABORED = 1 or
BREATHING_QUALITY_SHALLOW = 1
then RESPE = 1;
else RESPE = 0;
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if BREATHING_RATE_SLOW = 1 or
BREATHING_RATE_RAPID =1
then RESPR = 1;
else RESPR = 0;
If LUNG_SOUNDS_L_DIMINISHED = 1 or
LUNG_SOUNDS_R_DIMINISHED = 1 or
LUNG_SOUNDS_L_WHEEZE = 1 or
LUNG_SOUNDS_R_WHEEZE = 1
then RESPLS = 1;
else RESPLS = 0;
if dyspnea_sob =
(Resp_1 > 24 and
then RESPIRATORY
else RESPIRATORY

1 or RESPE = 1 or RESPR = 1 or RESPLS = 1 or SPO2 <= 92 or
age_year_conv >= 18)
= 1;
= 0;

*cardiovascular symptoms;
If lightheaded_dizzy = 1 or
_syncope = 1 or
chest_pain = 1 or
(pulse_1 >100 and age_year_conv > 18) or
pthypotensive = 1
then cardiovascular_rep = 1;
else cardiovascular_rep = 0;
*Adding _diarrhea = 1_or;
*nausea = 1 to symptoms increases cases by 7 cases;
*gastrointestinal symptoms;
If _vomiting = 1 or
abdominal_pain = 1 or
_diarrhea = 1 or
_nausea = 1
then gastrointestinal_rep = 1;
else gastrointestinal_rep = 0;
*Analysis of results determine that the following criteria is a balance
between
two extreme criteria of requiring trigger to not match versus a required
history of allergy.
Person must have an allergy history to have an unknown trigger considered.
where acute_onset = 1 and
(_trigger ne 6 or (_trigger =6 and (med_allergy_present = 1 or
env_allergy_present = 1)));
*NIAID Criteria #1
Previous Allergy History not necessary
When history included, only adds 7 cases
(med_allergy_present = 0 or env_allergy_present = 0);
If acute_onset = 1
and
(mucosocutaneous_rep = 1 and (cardiovascular_rep = 1 or respiratory_rep = 1))
then niaid_faan_criteria_one = 1;
else niaid_faan_criteria_one = 0;
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*NIAID Criteria #2
Allergy history possible inconsistent with trigger type;
if acute_onset = 1
and
((med_allergy_present = 1 and _trigger = 2) or
(food_allergy = 1 and _trigger = 1) or
(environmental_allergy = 1 and _trigger = 4) or
(_envenomation = 1 and _trigger = 3) and
pthypotensive = 0)
and
((_trigger = 6 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 1 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 2 and env_allergy_present = 1) or
(_trigger = 3 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 5 and env_allergy_present = 1) or
(_trigger = 7))
and
((mucosocutaneous_rep = 1 and cardiovascular_rep = 1) or
(mucosocutaneous_rep = 1 and respiratory_rep = 1) or
(mucosocutaneous_rep = 1 and gastrointestinal_rep = 1) or
(respiratory_rep = 1 and cardiovascular_rep = 1) or
(respiratory_rep = 1 and gastrointestinal_rep = 1) or
(cardiovascular_rep = 1 and gastrointestinal_rep = 1))
then niaid_faan_criteria_two = 1;
else niaid_faan_criteria_two = 0;
*NIAID Criteria #3
Previous Allergy History matches type of trigger.
Generalized to Medications, Food, Envenomations, Environmental.
Other and Unknown excluded;
if acute_onset = 1
and
((med_allergy_present = 1 and _trigger = 2) or
(food_allergy = 1 and _trigger = 1) or
(environmental_allergy = 1 and _trigger = 4) or
(_envenomation = 1 and _trigger = 3) or
_trigger = 7)
and
pthypotensive = 1
then niaid_faan_criteria_three = 1;
else niaid_faan_criteria_three = 0;
*NIAID Criteria Met;
if niaid_faan_criteria_one = 1 or niaid_faan_criteria_two = 1 or
niaid_faan_criteria_three = 1
then niaid_criteria_met = 1;
else niaid_criteria_met = 0;
*EMS Epinepherine given on PCR;
If Medication_1 =: "EPI" or Medication_1
Medication_2 =: "EPI" or Medication_2 =:
Medication_3 =: "EPI" or Medication_3 =:
Medication_4 =: "EPI" or Medication_4 =:
Medication_5 =: "EPI" or Medication_5 =:
Medication_6 =: "EPI" or Medication_6 =:

=: "Epi" or
"Epi" or
"Epi" or
"Epi" or
"Epi" or
"Epi"
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then ems_epi_given = 1;
else ems_epi_given = 0;
If ems_epi_given = 1 or epi_given = 1
then overallepigiven = 1;
else overallepigiven = 0;
*EMS Zofran given on PCR;
If Medication_1 =: "ondan"
Medication_2 =: "ondan" or
Medication_3 =: "ondan" or
Medication_4 =: "ondan" or
Medication_5 =: "ondan" or
Medication_6 =: "ondan" or
then ems_zofran_given = 1;
else ems_zofran_given = 0;

or Medication_1
Medication_2 =:
Medication_3 =:
Medication_4 =:
Medication_5 =:
Medication_6 =:

=: "ondan" or
"ondan" or
"ondan" or
"ondan" or
"ondan" or
"ondan"

*mucosocutaneous symptoms, Campbell Criteria using both PCR and select
Narrative;
If SKIN_COND_HIVES = 1 or
SKIN_COND_ITCHY = 1 or _pruritis = 1 or
SKIN_COLOR_FLUSHED = 1 or
SKIN_COND_SWOLLEN = 1 or swelling_face_lips = 1 or swelling_tongue_tingling =
1
then mucosocutaneous_repc = 1;
else mucosocutaneous_repc = 0;
*respiratory symptoms, Campbell Criteria using both PCR and select Narrative;
If dyspnea_sob = 1 or BREATHING_QUALITY_LABORED = 1 or
BREATHING_QUALITY_SHALLOW = 1 or
LUNG_SOUNDS_L_WHEEZE = 1 or LUNG_SOUNDS_R_WHEEZE = 1 or
AIRWAY_STRIDOR = 1 or SPO2 <= 92
then respiratory_repc = 1;
else respiratory_repc= 0;
*cardiovascular symptoms, Campbell Criteria Narrative Only;
If lightheaded_dizzy = 1 or
_syncope = 1 or
chest_pain = 1 or
(pulse_1 >100 and age_year_conv > 18) or
pthypotensive = 1
then cardiovascular_repc = 1;
else cardiovascular_repc = 0;
*gastrointestinal symptoms, Campbell criteria narrative only;
*Adding _diarrhea = 1_or nausea = 1 to symptoms increases cases by 7 cases;
If _vomiting = 1 or
abdominal_pain = 1 or
_diarrhea = 1 or
_nausea = 1
then gastrointestinal_repc = 1;
else gastrointestinal_repc= 0;
*Campbell criteria analysis;
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*Analysis of results determine that the following criteria is a balance
between
two extreme criteria of requiring trigger to not match versus a required
history of allergy.
Person must have an allergy history to have an unknown trigger considered.
where acute_onset = 1 and
(_trigger ne 6 or (_trigger =6 and (med_allergy_present = 1 or
env_allergy_present = 1)));
*NIAID Criteria #1
Previous Allergy History not necessary
When history included, only adds 7 cases
(med_allergy_present = 0 or env_allergy_present = 0);
If acute_onset = 1 and
(mucosocutaneous_repc = 1 and (cardiovascular_repc = 1 or respiratory_repc =
1))
then niaid_faan_criteria_onec = 1;
else niaid_faan_criteria_onec = 0;
*NIAID Criteria #2
Allergy history possible inconsistent with trigger type;
if acute_onset = 1
and
((med_allergy_present = 1 and _trigger = 2) or
(food_allergy = 1 and _trigger = 1) or
(environmental_allergy = 1 and _trigger = 4) or
(_envenomation = 1 and _trigger = 3) and
pthypotensive = 0)
and
((_trigger = 6 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 1 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 2 and env_allergy_present = 1) or
(_trigger = 3 and (med_allergy_present = 1 or env_allergy_present = 1)) or
(_trigger = 5 and env_allergy_present = 1) or
(_trigger = 7))
and
((mucosocutaneous_repc = 1 and cardiovascular_repc = 1) or
(mucosocutaneous_repc = 1 and respiratory_repc = 1) or
(mucosocutaneous_repc = 1 and gastrointestinal_repc = 1) or
(respiratory_repc = 1 and cardiovascular_repc = 1) or
(respiratory_repc = 1 and gastrointestinal_repc = 1) or
(cardiovascular_repc = 1 and gastrointestinal_repc = 1))
then niaid_faan_criteria_twoc = 1;
else niaid_faan_criteria_twoc = 0;
*NIAID Criteria #3
Previous Allergy History matches type of trigger.
Generalized to Medications, Food, Envenomations, Environmental.
Other and Unknown excluded;
if acute_onset = 1 and
((med_allergy_present = 1 and _trigger = 2) or
(food_allergy = 1 and _trigger = 1) or
(environmental_allergy = 1 and _trigger = 4) or
(_envenomation = 1 and _trigger = 3) or
_trigger = 7) and
pthypotensive = 1
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then niaid_faan_criteria_threec = 1;
else niaid_faan_criteria_threec = 0;
*NIAID Criteria Met;
if niaid_faan_criteria_onec = 1 or niaid_faan_criteria_twoc = 1 or
niaid_faan_criteria_threec = 1
then niaid_criteria_metc = 1;
else niaid_criteria_metc = 0;
*medication given by others;
if epi_given = 1 and epi_pta = 1 and epi_given_by = 2
then school_epi=1;
else school_epi=0;
if epi_given=1 and epi_pta = 1 and epi_given_by =5
then mp_epi = 1;
else mp_epi = 0;
*NYC BLS Protocol Adherence and NIAID Criteria Comparison;
*Compensated shock defined as BP above 90 with AMS, tachycardia, pale skin
(pallor) or cool, clammy skin (moist.diaphoretic)
Decompensated shock defined as BP below 90 witrh S&Sx as listed above.
Sever respriatory distres is defined as stidor or severe bochospasm, we
include labored and/or shallow breathing, and
diminished lungs sounds as complimentary to the definition of severe
bronchospasm)
History of allergic reaction and/or exposure to an allergen or inciting agent
Lightheaded dizzy and syncope included in AMS criteria for shock
Adult Compensated Shock definition
((mental_status_change_ams = 1 or lightheaded_dizzy = 1 or _syncope = 1 or
MENTAL_STATUS NE 'A') or pttachy = 1 or SKIN_COLOR_PALE = 1 or
SKIN_TEMP_COOL = 1 or (SKIN_COND_MOIST = 1 or SKIN_COND_DIAPHORETIC = 1)) and
pthypotensive = 1
For the purposes of the initial run we will use definition of decompensated
shock as the protocol
defines hyptensive shock;
if (acute_onset = 1 and age_year_conv >= 14) and
((med_allergy_present = 1 or env_allergy_present = 1) or _trigger ne 6) and
((AIRWAY_STRIDOR = 1 or
(LUNG_SOUNDS_L_WHEEZE = 1 or LUNG_SOUNDS_R_WHEEZE = 1 and
(BREATHING_QUALITY_LABORED = 1 or BREATHING_QUALITY_SHALLOW = 1 or
LUNG_SOUNDS_L_DIMINISHED = 1 or LUNG_SOUNDS_R_DIMINISHED = 1)))) or
((mental_status_change_ams = 1 or lightheaded_dizzy = 1 or _syncope = 1 or
MENTAL_STATUS NE 'A') or pttachy = 1 or
SKIN_COLOR_PALE = 1 or SKIN_TEMP_COOL = 1 or (SKIN_COND_MOIST = 1 or
SKIN_COND_DIAPHORETIC = 1)) and
pthypotensive = 1
then nyc_adult_protocol_might_apply = 1;
else nyc_adult_protocol_might_apply = 0;
*Pediatric compensated shock defined as AMS, tachycardia, pale skin (pallor)
or cool, clammy skin (moist.diaphoretic)
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without the indication of a low blood pressure. It is unlikely that
providers would wait to see hypotension
in this patient class to define shock, though it is listed in the protocol as
hypotensive shock. Therefore, we will not use
the hyptension criteria in the initial runs.
Sever respriatory distres is defined as stidor or severe bochospasm, we
include labored and/or shallow breathing, and
diminished lungs sounds as complimentary to the definition of severe
bronchospasm)
History of allergic reaction and/or exposure to an allergen or inciting agent
Lightheaded dizzy and syncope included in AMS criteria for shock;
if (acute_onset = 1 and 0 < age_year_conv < 14) and
((med_allergy_present = 1 or env_allergy_present = 1) or _trigger ne 6) and
((AIRWAY_STRIDOR = 1 or
(LUNG_SOUNDS_L_WHEEZE = 1 or LUNG_SOUNDS_R_WHEEZE = 1 and
(BREATHING_QUALITY_LABORED = 1 or BREATHING_QUALITY_SHALLOW = 1 or
LUNG_SOUNDS_L_DIMINISHED = 1 or LUNG_SOUNDS_R_DIMINISHED = 1))) or
((mental_status_change_ams = 1 or lightheaded_dizzy = 1 or _syncope = 1 or
MENTAL_STATUS NE 'A') or
pttachy = 1 or SKIN_COLOR_PALE = 1 or SKIN_TEMP_COOL = 1 or SKIN_COND_MOIST =
1 or SKIN_COND_DIAPHORETIC = 1))
then nyc_child_protocol_might_apply = 1;
else nyc_child_protocol_might_apply = 0;
If nyc_adult_protocol_might_apply = 1 or nyc_child_protocol_might_apply = 1
then nyc_protocol_might_apply = 1;
else nyc_protocol_might_apply = 0;
If AIRWAY_PARTIALLY_OBSTRUCTED = 1
then obstructed = 1;
else obstructed = 0;
if AIRWAY_DIFFICULTY_SWALLOWING = 1
then dswallow = 1;
else dswallow = 0;
If AIRWAY_DROOLING = 1
then drooling = 1;
else drooling = 0;
If SKIN_COND_ERYTHEMA = 1
then erythema = 1;
else erythema = 0;
If SKIN_COND_HIVES = 1
then hives = 1;
else hives = 0;
If SKIN_COND_ITCHY = 1
then itchy = 1;
else itchy = 0;
If SKIN_COND_SWOLLEN = 1
then swollen = 1;
else swollen = 0;
If SKIN_COND_RASH = 1
then rash = 1;
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else rash = 0;
if SKIN_COLOR_FLUSHED = 1
then flushed = 1;
else flushed = 0;
If AIRWAY_STRIDOR = 1
then stridor = 1;
else stridor = 0;
If BREATHING_QUALITY_LABORED = 1
then labored = 1;
else labored = 0;
If LUNG_SOUNDS_L_DIMINISHED = 1 or LUNG_SOUNDS_R_DIMINISHED = 1
then diminished = 1;
else diminished = 0;
If LUNG_SOUNDS_L_WHEEZE = 1 or LUNG_SOUNDS_R_WHEEZE =1
then wheeze = 1;
else wheeze = 0;
If BREATHING_QUALITY_SHALLOW = 1
then shallow = 1;
else shallow = 0;
If BREATHING_RATE_SLOW = 1
then slow = 1;
else slow = 0;
If BREATHING_RATE_RAPID =1
then rapid = 1;
else rapid = 0;
If 0 < SPO2 <= 92
then SPOX = 1;
else SPOX = 0;
If Resp_1 > 24 and age_year_conv >= 18
then resprate24 = 1;
else resprate24 = 0;
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APPENDIX G-Population Choropleth Maps
Choropleth presentations of population count and population density for the individual census
tracts in Richmond County.

Figure 2.2-Population Count by Census Tract

Figure 2.3-Population Density by Census Tract
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APPENDIX H-SaTScan Results
Table 2.4-SaTScan Results for Census Tract Clusters. *
Census Cluster
146.04, 146.07, 156.01,
156.02, 170.05, 170.07,
170.08, 170.09, 170.1,
170.11, 170.12, 176,
198, 208.01, 208.03,
208.04, 226, 228,
244.01, 244.02, 248
29, 40
114.01
18, 20.02, 64, 70, 74
146.04, 146.07, 170.05,
170.07, 170.08, 170.09,
170.1, 170.11, 170.12,
208.01, 208.03, 208.04,
226, 228
74
70
146.04, 146.07, 146.08,
156.02, 170.05, 170.07,
170.08, 170.09, 170.1,
170.11, 170.12, 176,
198, 208.01, 208.03,
208.04, 226, 228, 248
70, 96.02, 112.01,
112.02, 114.01, 114.02
125, 133.01, 133.02,
141, 151, 189.01,
189.02, 197, 201, 207,
213, 223, 231, 239,
247, 251, 273.01,
291.03, 291.04, 303.01,
303.02, 319.01, 319.02,
323

History

Hot/Cold

P_VALUE

OBSERVED

EXPECTED

REL_RISK

A

Cold

<.0001

279

409

0.6234

A
A
A

Hot
Hot
Hot

<.0001
0.0009
0.0039

164
94
331

108
61
272

1.5793
1.5599
1.2645

E

Cold

0.0029

142

192

0.7153

E
E

Cold
Hot

0.0580
<.0001

17
183

34
124

0.4814
1.5386

AE

Cold

<.0001

27

62

0.3786

AE

Hot

<.0001

107

63

2.1180

AE

Hot

0.0011

25

9

3.0291

8, 17, 20.01, 21, 27, 29,
33, 36, 39, 40, 47, 50,
59, 64, 67, 75, 96.01,
M
Cold
0.0046
3560
3667
0.9642
105, 121, 125, 147,
169.01, 173, 177
70, 96.02, 112.01,
112.02, 114.01, 114.02,
M
Hot
0.0240
4819
4716
1.0294
122
*-Significant clusters (p-value <0.10) are presented below. A-Asthma History, E-Environmental Allergy History,
AE-Both Asthma and Environmental Allergy History, M-Medication Allergy History.
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